0001019687-16-006369.txt : 20160517 0001019687-16-006369.hdr.sgml : 20160517 20160517164408 ACCESSION NUMBER: 0001019687-16-006369 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 59 CONFORMED PERIOD OF REPORT: 20160331 FILED AS OF DATE: 20160517 DATE AS OF CHANGE: 20160517 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Rennova Health, Inc. CENTRAL INDEX KEY: 0000931059 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMPUTER PROCESSING & DATA PREPARATION [7374] IRS NUMBER: 680370244 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35141 FILM NUMBER: 161658042 BUSINESS ADDRESS: STREET 1: 400 S. AUSTRALIAN AVENUE, SUITE 800 CITY: WEST PALM BEACH STATE: FL ZIP: 33401 BUSINESS PHONE: 561-855-1626 MAIL ADDRESS: STREET 1: 400 S. AUSTRALIAN AVENUE, SUITE 800 CITY: WEST PALM BEACH STATE: FL ZIP: 33401 FORMER COMPANY: FORMER CONFORMED NAME: CollabRx, Inc. DATE OF NAME CHANGE: 20120926 FORMER COMPANY: FORMER CONFORMED NAME: TEGAL CORP /DE/ DATE OF NAME CHANGE: 19950918 10-Q 1 rennova_10q-033116.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2016

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______ to ______.

Commission File Number: 001-35141

RENNOVA HEALTH, INC.

(Exact name of registrant as specified in its charter)

Delaware			68-370244
(State or other jurisdiction of incorporation or organization)			(IRS Employer Identification No.)

400 South Australian Ave., 8^th Floor West Palm Beach, FL			33401
(Address of principal executive offices)			(Zip Code)

(561) 855-1626

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act:

Large accelerated filer o	Accelerated filer o
Non-accelerated filer o (Do not check if a smaller reporting company)	Smaller reporting company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

As of May 9, 2016, the registrant had 14,782,557 shares of its Common Stock, $0.01 par value, outstanding.

RENNOVA HEALTH, INC.

FORM 10-Q

March 31, 2016

TABLE OF CONTENTS

PART I – FINANCIAL INFORMATION		3

Item 1.	Financial Statements	3
	Condensed Consolidated Balance Sheets as of March 31, 2016 (unaudited) and December 31, 2015	3
	Condensed Consolidated Statements of Operations for the three months ended March 31, 2016 and 2015 (unaudited)	5
	Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2016 and 2015 (unaudited)	6
	Notes to Condensed Consolidated Financial Statements (unaudited)	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	20
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	27
Item 4.	Controls and Procedures	27

PART II – OTHER INFORMATION		29

Item 1.	Legal Proceedings	29
Item 1A.	Risk Factors	29
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	29
Item 3.	Defaults Upon Senior Securities	30
Item 4.	Mine Safety Disclosures	30
Item 5.	Other Information	30
Item 6.	Exhibits	30

SIGNATURES		31

RENNOVA HEALTH, INC.

Condensed Consolidated Balance Sheets

	March 31,		December 31,
	2016		2015
	(unaudited)
ASSETS

Current assets:
Cash	$	4,900,806	$	8,833,230
Accounts receivable, net		7,051,842		8,149,484
Prepaid expenses and other current assets		1,317,948		1,193,077
Income tax refunds receivable		2,516,028		2,415,013

Total current assets		15,786,624		20,590,804

Property and equipment, net		6,449,872		7,148,295

Other assets:
Deposits		232,774		232,774

Total assets	$	22,469,270	$	27,971,873

See accompanying notes to condensed consolidated financial statements.

RENNOVA HEALTH, INC.

Condensed Consolidated Balance Sheets (Continued)

	March 31,			December 31,
	2016			2015
	(unaudited)
LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:
Accounts payable	$	3,436,654		$	4,360,035
Accrued expenses		4,600,474			5,285,455
Current portion of notes payable		5,269,031			269,031
Current portion of notes payable, related party		4,174,742			5,133,888
Current portion of capital lease obligations		1,323,708			1,323,708

Total current liabilities		18,804,609			16,372,117

Other liabilities:
Notes payable, net of current portion		2,898,242			2,903,898
Capital lease obligations, net of current portion		2,070,990			2,394,171
Derivative liabilities		4,123,929			7,495,486

Total liabilities		27,897,770			29,165,672

Commitments and contingencies

Stockholders' equity:
Preferred stock, 5,000,000 shares authorized:
Series B preferred stock, $0.01 par value, 5,000 shares authorized, issued and outstanding at March 31, 2016 and December 31, 2015		50			50
Series C preferred stock, $0.01 par value, 10,350 shares authorized, 8,818 and 9,000 shares issued and outstanding at March 31, 2016 and December 31, 2015, respectively		88			90
Series E preferred stock, $0.01 par value, 45,000 shares authorized, issued and outstanding at March 31, 2016 and December 31, 2015		450			450
Common stock, $0.01 par value, 500,000,000 shares authorized, 14,782,557 shares issued and outstanding at March 31, 2016, 50,000,000 shares authorized, 14,651,837 shares issued and outstanding at December 31, 2015		147,825			143,951
Additional paid-in-capital		26,694,274			26,688,837
(Accumulated deficit) retained earnings		(32,271,187	)		(28,027,177	)
Total stockholders' equity		(5,428,500	)		(1,193,799	)

Total liabilities and stockholders' equity	$	22,469,270		$	27,971,873

See accompanying notes to condensed consolidated financial statements.

RENNOVA HEALTH, INC.

Condensed Consolidated Statements of Operations

(unaudited)

	Three Months Ended
	March 31,
	2016			2015
Net Revenues	$	1,878,813		$	13,648,782

Operating expenses:
Direct costs of revenue		564,200			4,031,274
General and administrative		5,954,046			5,639,933
Sales and marketing expenses		873,440			1,182,221
Engineering		522,768			–
Bad debt		1,285			–
Depreciation and amortization		727,270			580,793
Total operating expenses		8,643,009			11,434,221

Income (loss) from operations		(6,764,196	)		2,214,561

Other income (expense):
Other income		100,010			21
Unrealized gain (loss) on derivative instruments		3,433,588			–
Gain (loss) on legal settlement		–			275,028
Interest expense		(1,013,413	)		(505,101	)
Total other income (expense)		2,520,185			(230,052	)

Income (loss) before income taxes		(4,244,011	)		1,984,509

Provision for income taxes		–			977,500

Net income (loss) attributable to Rennova Health		(4,244,011	)		1,007,009

Preferred stock dividends		–			523,050

Net income (loss) attributable to Rennova Health common shareholders	$	(4,244,011	)	$	483,959

Net income (loss) per common share:
Basic	$	(0.29	)	$	0.04
Diluted	$	(0.29	)	$	0.04

Weighted average number of common shares outstanding during the period:
Basic		14,816,586			11,937,530
Diluted		14,816,586			12,809,335

See accompanying notes to condensed consolidated financial statements.

RENNOVA HEALTH, INC.

Condensed Consolidated Statements of Cash Flows

(unaudited)

	Three Months Ended March 31,
	2016			2015

Cash flows provided by (used in) operating activities:
Net income (loss)	$	(4,244,011	)	$	1,007,009
Adjustments to reconcile net income (loss) to net cash provided by operations:
Depreciation and amortization		727,270			580,793
Non-cash gain on derivative instruments		(3,433,588	)		–
Stock issued in lieu of cash compensation		9,310			300,000
Stock-based compensation		–			56,463
Bad debts		1,285			6,473,733
Accretion of beneficial conversion feature as interest		789,376			246,575
Accretion of debt discount		–			93,699
Gain on extinguishment of debt		(100,000	)		–
Gain on legal settlement		–			(275,028	)
Changes in operating assets and liabilities:
Accounts receivable		1,096,357			(12,843,394	)
Prepaid expenses and other current assets		(126,863	)		(16,935	)
Security deposits		–			(39,222	)
Accounts payable		(923,381	)		(299,697	)
Accrued expenses		(684,981	)		417,102
Income tax assets and liabilities		(101,015	)		457,769
Deferred tax liabilities		–			48,900
Net cash used in operating activities		(6,990,241	)		(3,792,233	)

Cash flows provided by (used in) investing activities:
Purchase of property and equipment		(19,002	)		(213,142	)
Net cash used in investing activities		(19,002	)		(213,142	)

Cash flows provided by (used in) financing activities:
Dividends on Series B preferred stock		–			(523,050	)
Proceeds from issuance of notes payable, related party		3,000,000			–
Proceeds from issuance of notes payable		5,000,000			3,030,000
Payments on notes payable		(4,600,000	)		(60,000	)
Payments on capital lease obligations		(323,181	)		(197,316	)
Net cash provided by financing activities		3,076,819			2,249,634

Net decrease in cash		(3,932,424	)		(1,755,741	)

Cash at beginning of period		8,833,230			2,406,246

Cash at end of period	$	4,900,806		$	650,505

Supplemental disclosure of cash flow information:
Cash paid for interest	$	520,000		$	160,835
Cash paid for taxes	$	–		$	470,831

Non-cash investing and financing activities:
Acquisition of noncontrolling interest in Biohealth Medical Laboratory, Inc.:
Deposits on acquisitions	$	–		$	259,875
Goodwill	$	–		$	(138,871	)
Noncontrolling interest	$	–		$	(121,004	)

See accompanying notes to condensed consolidated financial statements.

RENNOVA HEALTH, INC.

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 1 – Organization and Presentation

Rennova Health, Inc. (“Rennova”), together with its subsidiaries (the “Company”, “we”, “us” or “our”), is a vertically integrated provider of healthcare related products and services. Our principal lines of business are clinical laboratory operations, supportive software solutions, which includes EHR (Electronic Health Records), Medical Billing Services, and LIS (Lab Information Services), and decision support and informatics operations. We present our financial results based upon our three business segments listed above.

Merger between the Company and Medytox Solutions, Inc.

On November 2, 2015, pursuant to the terms of the Agreement and Plan of Merger, dated as of April 15, 2015, by and among the Company, CollabRx Merger Sub, Inc. (“Merger Sub”), a direct wholly-owned subsidiary of the Company formed for the purpose of the merger, and Medytox Solutions, Inc. (“Medytox”), Merger Sub merged with and into Medytox, with Medytox as the surviving company and a direct, wholly-owned subsidiary of the Company (the “Merger”). Prior to closing, the Company amended its certificate of incorporation to effect a 1-for-10 reverse stock split and to change its name to Rennova Health, Inc. In connection with the Merger, (i) each share of common stock of Medytox was converted into the right to receive approximately 0.4096 shares of common stock of the Company, (ii) each share of Series B Preferred Stock of Medytox was converted into the right to receive one share of a newly-authorized Series B Convertible Preferred Stock of the Company, and (iii) each share of Series E Convertible Preferred Stock of Medytox was converted into the right to receive one share of a newly-authorized Series E Convertible Preferred Stock of the Company. This transaction has been accounted for as a reverse merger in accordance with Generally Accepted Accounting Principles in the United States ("US GAAP") and, as such, the financial statements presented prior to November 2, 2015 are those of Medytox and the financial statements presented after November 2, 2015 reflect the operations, of the combined company. All common share amounts prior to November 2, 2015 have been retroactively restated to reflect the conversion ratio.

Holders of Company equity prior to the closing of the Merger (including all outstanding Company common stock and all restricted stock units, options and warrants exercisable for shares of Company common stock) held 10% of the Company's common stock immediately following the closing of the Merger, and holders of Medytox equity prior to the closing of the Merger (including all outstanding Medytox common stock and all outstanding options exercisable for shares of Medytox common stock, but less certain options that were cancelled upon the closing pursuant to agreements between Medytox and such optionees) held 90% of the Company's common stock immediately following the closing of the Merger, in each case on a fully diluted basis, provided, however, outstanding shares of the newly designated Series B Convertible Preferred Stock and Series E Convertible Preferred Stock, certain outstanding convertible promissory notes exercisable for Company common stock after the closing and certain option grants expected to be made following the closing of the Merger are excluded from such ownership percentages.

On November 3, 2015, the common stock of Rennova Health, Inc. commenced trading on the Nasdaq Capital Market under the symbol “RNVA.” Prior to that date, our common stock was listed on the NASDAQ Capital Market under the symbol “CLRX.” Immediately after the consummation of the Merger, the Company had 13,750,010 shares of common stock, 5,000 shares of Series B Convertible Preferred Stock and 45,000 shares of Series E Convertible Preferred Stock issued and outstanding.

Potential De-Listing of the Company’s Stock

On March 16, 2016, the Company was notified by Nasdaq that the bid price of the Company's common stock closed below the minimum $1.00 share requirement for continued inclusion under Nasdaq Rule 5550(a)(2) (the “Bid Price Rule”). In accordance with Nasdaq Rule 5810(c)(3)(A), the Company has 180 calendar days, or until September 12, 2016, to regain compliance. If at any time before September 12, 2016, the bid price of the Company's common stock closes at $1.00 per share or more for a minimum of 10 consecutive business days, the Company will regain compliance with the Bid Price Rule. If the Company does not regain compliance by September 12, 2016, an additional 180 days may be granted to regain compliance, so long as the Company meets The Nasdaq Capital Market initial listing criteria (except for the bid price requirement).

On April 26, 2016, the Company was notified by Nasdaq that the stockholders’ equity balance reported on its Form 10-K for the year ended December 31, 2015 fell below the $2,500,000 minimum requirement for continued listing under the Nasdaq Capital Market’s Listing Rule 5550(b)(1) (the “Equity Rule”). As of December 31, 2015, the Company’s stockholder’s equity balance was $(1,193,799). In accordance with the Equity Rule, the Company has until June 10, 2016 to prepare and submit a plan to Nasdaq outlining how it intends to regain compliance. If the plan is accepted, the Company can be granted up to 180 calendar days from April 26, 2016 to evidence compliance. There can be no guarantee that the Company will be able to regain compliance with the continued listing requirement of the Equity Rule or that its plan will be accepted by Nasdaq.

RENNOVA HEALTH, INC.

Notes to Condensed Consolidated Financial Statements

(unaudited)

Basis of Presentation

The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with US GAAP for interim financial statement presentation and in accordance with Form 10-Q. Accordingly, they do not include all of the information and footnotes required in annual financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements contain all adjustments (consisting only of normal recurring accruals) necessary to present fairly the financial position and results of operations and cash flows for the interim periods reported in this Form 10-Q. The results of operations presented are not necessarily indicative of the results to be expected for any other interim period or for the entire year.

These unaudited interim condensed consolidated financial statements should be read in conjunction with the 2015 audited annual financial statements included in the Annual Report on Form 10-K/A, filed with the U.S. Securities and Exchange Commission (“SEC”) on May 17, 2016.

The Company’s consolidated financial statements are prepared using US GAAP applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, the Company has recently accumulated significant losses and has negative cash flows from operations, which raise substantial doubt about its ability to continue as a going concern. Management's plans with respect to alleviating the adverse financial conditions that caused management to express substantial doubt about the Company’s ability to continue as a going concern are as follows:

The Company is currently executing on a plan of action to increase the volume of samples processed by its labs. In addition, the Company is executing on a plan of action to increase the number of customers for its supportive software solutions. While the results of these plans of action are encouraging, no conclusion can be drawn at this time about the ultimate efficacy of these plans of action.

In order to support the Company’s continued operations, the Company received proceeds of $5,000,000 from pledging certain of its accounts receivable as collateral to a prepaid forward purchase contract. The Company is also entitled to $2,516,028 in income tax refunds, the claim for which was filed with the IRS in early April 2016. There can be no assurance as to the timing of the receipt of the income tax refunds for which the Company has filed.

There can be no assurance that the Company will be able to achieve its business plans, raise any more required capital or secure the financing necessary to achieve its current operating plan. The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plan described in the preceding paragraphs and eventually regain profitable operations. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

RENNOVA HEALTH, INC.

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 2 – Accounts Receivable

Accounts receivable at March 31, 2016 and December 31, 2015 consisted of the following:

	March 31,			December 31,
	2016			2015
Accounts receivable - clinical laboratory operations	$	96,227,506		$	105,332,339
Accounts receivable - supportive software solutions		329,395			569,351

Total accounts receivable		96,556,901			105,901,690
Less:
Allowance for discounts		(89,328,698	)		(97,577,130	)
Allowance for bad debts		(176,361	)		(175,076	)

Accounts receivable, net	$	7,051,842		$	8,149,484

Note 3 – Long-Lived Assets

Property and equipment at March 31, 2016 and December 31, 2015 consisted of the following:

	March 31,			December 31,
	2016			2015
Medical equipment	$	922,551		$	991,903
Equipment		577,316			547,555
Equipment under capital leases		5,663,333			5,663,332
Furniture		561,688			560,400
Leasehold improvements		1,776,957			1,760,125
Vehicles		196,534			196,534
Computer equipment		753,225			661,234
Software		1,837,174			1,878,848

		12,288,778			12,259,931
Less accumulated depreciation		(5,838,906	)		(5,111,636	)
Property and equipment, net	$	6,449,872		$	7,148,295

Depreciation of property and equipment was $727,270 and $580,793 for the three months ended March 31, 2016 and 2015, respectively.

Management periodically reviews the valuation of long-lived assets for potential impairments. Management has not recognized an impairment of these assets to date.

RENNOVA HEALTH, INC.

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 4 – Notes Payable

The Company and its subsidiaries are party to a number of loans with affiliates and unrelated parties. At March 31, 2016 and December 31, 2015, notes payable consisted of the following:

Notes Payable – Third Parties

	March 31, 2016
	Face Value		Unamortized			Fair Value of		Net Value
	of Note		Discount			Derivatives		of Note
Loan payable under prepaid forward purchase contract in the amount of $5,000,000, at 20% interest, with no payments of interest or principal through March 30, 2017. All outstanding amounts are due March 30, 2017.	$	5,000,000	$	–		$	–	$	5,000,000

Loan payable to TCA Global Master Fund, LP in the amount of $3,000,000, at 16% interest, with interest only payments monthly through September 11, 2016. Principal and interest payments are due monthly from October 11, 2016 through September 11, 2017.		3,000,000		(305,188	)		130,849		2,825,661

Loan payable to CommerceNet in the amount of $250,000 at 1.06% interest, increasing to 6% after two years. Principal and interest payments are made annually from July 12, 2015 through July 12, 2017.		170,806		–			–		170,806

Loan payable to Jay Tenebaum in the amount of $250,000 at 1.06% interest, increasing to 6% after two years. Principal and interest payments are made annually from July 12, 2015 through July 12, 2017.		170,806		–			–		170,806

	$	8,341,612	$	(305,188	)	$	130,849		8,167,273

Less current portion									(5,269,031	)

Notes payable, net of current portion								$	2,898,242

RENNOVA HEALTH, INC.

Notes to Condensed Consolidated Financial Statements

(unaudited)

	December 31, 2015
	Face Value		Unamortized			Fair Value of		Net Value
	of Note		Discount			Derivatives		of Note
Loan payable to former shareholder of Epinex Diagnostics Laboratories, Inc. in the amount of $400,000, at 0% interest, with principal payments of $100,000 due in periodic installments from November 26, 2014 through February 26, 2016. Amount recorded is net of imputed discount of $1,775 at December 31, 2015.	$	100,000	$	(1,775	)	$	–	$	98,225

Loan payable to TCA Global Master Fund, LP in the amount of $3,000,000, at 16% interest, with interest only payments monthly through September 11, 2016. Principal and interest payments are due monthly from October 11, 2016 through September 11, 2017.		3,000,000		(453,025	)		186,117		2,733,092

Loan payable to CommerceNet in the amount of $250,000 at 1.06% interest, increasing to 6% after two years. Principal and interest payments are made annually from July 12, 2015 through July 12, 2017.		170,806		–			–		170,806

Loan payable to Jay Tenebaum in the amount of $250,000 at 1.06% interest, increasing to 6% after two years. Principal and interest payments are made annually from July 12, 2015 through July 12, 2017.		170,806		–			–		170,806

	$	3,441,612	$	(454,800	)	$	186,117		3,172,929

Less current portion									(269,031	)

Notes payable, net of current portion								$	2,903,898

RENNOVA HEALTH, INC.

Notes to Condensed Consolidated Financial Statements

(unaudited)

Notes Payable – Related Parties

	March 31, 2016
	Face Value		Unamortized			Fair Value of		Net Value
	of Note		Discount			Derivatives		of Note
Convertible debenture dated December 31, 2014 in the amount of $3,000,000 which bears interest at 10% and is due December 31, 2016. The note provides the lender, D&D Funding II, LLC, the option to convert the note into the Company's common stock at a 25% discount to the average trading price (as defined in the note agreement) for the ten consecutive trading days prior to the conversion date.	$	3,000,000	$	(1,588,495	)	$	2,263,237	$	3,674,742

Loan payable to Alcimede, LLC in the amount of $3,000,000, at 6% interest, with one payment of $3,000,000, plus interest, due on February 2, 2017. (On June 29, 2015, Alcimede exercised options to purchase 1,000,000 shares for $2,500,000, which reduced the loan.)	$	500,000		–			–	$	500,000

Current portion of notes payable, related party	$	3,500,000	$	(1,588,495	)	$	2,263,237	$	4,174,742

	December 31, 2015
	Face Value		Unamortized			Fair Value of		Net Value
	of Note		Discount			Derivatives		of Note
Convertible debenture dated December 31, 2014 in the amount of $3,000,000 which bears interest at 10% and is due December 31, 2016. The note provides the lender, D&D Funding II, LLC, the option to convert the note into the Company's common stock at a 25% discount to the average trading price (as defined in the note agreement) for the ten consecutive trading days prior to the conversion date.	$	3,000,000	$	(2,236,112	)	$	2,270,000	$	3,033,888

Loan payable to Alcimede, LLC in the amount of $3,000,000, at 6% interest, with one payment of $3,000,000, plus interest, due on February 2, 2016. (On June 29, 2015, Alcimede exercised options to purchase 1,000,000 shares for $2,500,000, which reduced the loan.)	$	500,000		–			–	$	500,000

Loan payable to Christopher Diamantis in the amount of $1,600,000. One payment of $1,600,000 due January 7, 2016 plus $100,000 of interest.	$	1,600,000		–			–	$	1,600,000

Current portion of notes payable, related party	$	5,100,000	$	(2,236,112	)	$	2,270,000	$	5,133,888

Convertible Debenture Dated December 31, 2014

On December 31, 2014, the Company borrowed $3,000,000 from D&D Funding II, LLC (“D&D”). Christopher Diamantis, a director of the Company, is the manager and 50% owner of D&D. In January 2016, the Company temporarily repaid $3,000,000 of the amounts due under the D&D note. In addition to the principal amount, the Company paid $300,000 in cash for interest for 2015. In March 2016, the Company re-borrowed 100% of the principal amount repaid in January 2016. This note is convertible into the Company’s Common Stock at a 25% discount to the trailing ten day average closing price at any time prior to the repayment. In the event of conversion, the holder of the note is also entitled to receive a number of warrants to purchase the Company’s Common Stock equal to the number of shares issued upon conversion with exercise prices equal to the trailing ten day average closing price of our Common Stock. These two features are derivative instruments that are re-valued quarterly and are reflected in the table above.

RENNOVA HEALTH, INC.

Notes to Condensed Consolidated Financial Statements

(unaudited)

Prepaid Forward Purchase Contract

On March 31, 2016, the Company entered into an agreement to pledge certain of its accounts receivable as collateral against a prepaid forward purchase contract. The receivables had an estimated collectable value of $8,700,000 and have been adjusted down to approximately $4,300,000 in our books and records. The consideration received was $5,000,000. In exchange for the consideration received, the counterparty received the right to: (i) a 20% per annum investment return from the Company on the consideration, with a minimum repayment term of six months and minimum return of $500,000, (ii) all payments recovered from the accounts receivable up to $5,250,000, if paid in full within six months, or $5,500,000, if not paid in full within six months, and (iii) 20% of all payments of the accounts receivable in excess of amounts received in (i) and (ii). On March 31, 2017, to the extent that the counterparty has not been paid $6,000,000, the Company is required to pay the difference. Christopher Diamantis, a director of the Company, guaranteed the Company's payment obligation of up to $6,000,000. For providing the guarantee, and to the extent that the counterparty receives amounts payable under clause (ii) above exceeding $5,000,000, Mr. Diamantis will be paid a fee by the counterparty equal to the amount by which the amount received under clause (ii) above exceeds $5,000,000 ($250,000 or $500,000, depending on the timing of payment).

Note 5 – Related Party Transactions

Alcimede LLC, of which the CEO of the Company is the sole manager, had advanced loans to the Company for the payment of certain operating expenses. The loans were non-interest bearing and were due on demand. Alcimede was paid $96,750 and $85,905 for consulting fees pursuant to a consulting agreement for the three months ended March 31, 2016 and 2015, respectively. On February 3, 2015, the Company borrowed $3,000,000 from Alcimede LLC. The note has an interest rate of 6% and is due on February 2, 2017. On June 29, 2015, Alcimede exercised options granted in October 2012 to purchase one million shares of the Company’s common stock at an exercise price of $2.50 per share. The loan outstanding was reduced in satisfaction of the aggregate exercise price of $2,500,000. On February 27, 2015, the Company borrowed $30,000 from Alcimede LLC and this loan was repaid on April 15, 2015.

On June 30, 2015, the Company issued 200,000 shares of common stock to SS International Consulting Ltd., of which a former director of the Company is the sole manager, pursuant to a consulting contract.

On September 4, 2015, the Company borrowed $500,000 from Christopher Diamantis, a director of the Company. This loan was repaid in the fourth quarter of 2015 with a 10% fee in cash. In the fourth quarter of 2015, the Company borrowed $1,600,000 from Mr. Diamantis which was due January 7, 2016. In January 2016, the Company repaid $1,600,000 of the amounts due Mr. Diamantis. In addition to the principal amount, the Company paid $100,000 in cash for interest.

On August 1, 2015, Medytox entered into a non-exclusive consulting agreement with Monarch Capital, LLC ("Monarch"). Michael Goldberg, at the time a director of Medytox and currently a director of the Company, is the Managing Director of Monarch. Under this agreement, Monarch provides business and financial advice. The term of the agreement is through August 31, 2016, and is subject to automatic renewal for an additional one year unless Medytox provides the consultant with 180 days prior written notice of its intent not to renew. Medytox paid $7,500 at signing and pays $12,500 a month for the first three months, $15,000 a month for the second three months, $17,500 a month for the third three months and $20,000 a month for the fourth three months. If the agreement is renewed for an additional year the monthly payment will increase by 5%.

All of these transactions were completed at arm’s length at values commensurate with those of independent third parties.

RENNOVA HEALTH, INC.

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 6 – Capital Lease Obligations

The Company leases various assets under capital leases expiring through 2020 as follows:

	March 31,			December 31,
	2016			2015
Medical equipment	$	5,663,333		$	5,663,332
Less accumulated depreciation		(2,443,384	)		(2,093,920	)

Net	$	3,219,949		$	3,569,412

Depreciation expense on assets under capital leases was $349,464 and $215,045 for the three months ended March 31, 2016 and 2015, respectively.

Aggregate future minimum rentals under capital leases are as follows:

December 31,
2016	$	1,217,765
2017		1,432,542
2018		845,330
2019		217,412
2020		32,611

Total		3,745,660

Less interest		350,962

Present value of minimum lease payments		3,394,698

Less current portion of capital lease obligations		1,323,708

Capital lease obligations, net of current portion	$	2,070,990

Note 7 – Stockholders’ Equity

Preferred Stock

During the three months ended March 31, 2015, the former Medytox Series B preferred shareholders earned dividends totaling $523,050. At March 31, 2016 and December 31, 2015, accrued dividends of $1,684,148 and $2,099,148, respectively, were included in accrued expenses. All outstanding Medytox Series B preferred shares were cancelled in connection with the Merger in exchange for shares of Rennova Series B Convertible Preferred Stock, which only receives dividends when dividends are declared on our common stock.

During the three months ended March 31, 2016, Series C preferred shareholders converted a total of 182 shares of Series C preferred stock into 117,420 shares of Common Stock.

Common Stock

During the three months ended March 31, 2016, the Company issued an aggregate of 13,300 shares of the Company’s common stock to a consultant for services. The Company recognized $9,310 in compensation costs associated with these issuances.

Stock Options

During the three months ended March 31, 2016 and 2015, no stock options were granted or forfeited.

RENNOVA HEALTH, INC.

Notes to Condensed Consolidated Financial Statements

(unaudited)

Basic and Diluted Income per Share

The following table presents the reconciliation of the numerators and denominators used in the calculation of earnings per share for the three months ended March 31, 2016 and 2015. For the three months ended March 31, 2015, all share and per share amounts have been restated as a result of the Merger.

	Three Months Ended March 31,
	2016			2015
Basic:
Numerator - net income (loss) available to common stockholders	$	(4,244,011	)		483,959
Denominator - weighted-average shares outstanding		14,816,586			11,937,530

Net income (loss) per share - Basic	$	(0.29	)	$	0.04

Diluted:
Numerator:
Net income (loss) available to common stockholders	$	(4,244,011	)	$	483,959
Interest expense on convertible debt, net of taxes		–			46,912
		(4,244,011	)		530,871

Denominator:
Weighted-average shares outstanding		14,816,586			11,937,530
Weighted-average equivalent shares options and warrants		–			354,901
Weighted-average equivalent shares from convertible debt		–			409,638
Weighted-average equivalent shares from Series C convertible preferred stock		–			–
Weighted-average equivalent shares from Series D convertible preferred stock		–			73,643
Weighted-average equivalent shares from Series E convertible preferred stock		–			33,623
		14,816,586			12,809,335

Net income (loss) per share - Diluted	$	(0.29	)	$	0.04

Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. As of March 31, 2016 and 2015, the following potential common stock equivalents were excluded from the calculation of Diluted EPS as their effect was anti-dilutive:

	March 31,		March 31,
	2016		2015
Stock options outstanding		1,822,675		9,923,474
Warrants outstanding		6,898,560		–
Convertible debt		8,791,343		–
Convertible preferred stock		11,422,977		–

		28,935,555		9,923,474

Note 8 – Income Taxes

The Company recognized no income tax expense or benefit for the three months ended March 31, 2016. The Company recognized income tax expense of $977,500 for the three months ended March 31, 2015. The Company’s effective income tax rates for the three months ended March 31, 2016 and 2015 were 0.0% and 49.3%, respectively.

Changes to the effective tax rates relate primarily to the recognition of a valuation allowance on 100% of net deferred tax assets for the three months ended March 31, 2016.

The Company applies a “more likely than not” threshold to the recognition and nonrecognition of tax positions. A change in judgment related to prior years’ tax positions is recognized in the quarter of such change. The Company had no reserve for uncertain tax positions as of March 31, 2016 or December 31, 2015. The Company recognizes interest and/or penalties related to income tax matters in income tax expense and in income taxes payable.

RENNOVA HEALTH, INC.

Notes to Condensed Consolidated Financial Statements

(unaudited)

The table below presents a reconciliation of statutory income tax rates to our effective rates:

	Three Months Ended March 31,
	2016		2015
Expected federal income tax at statutory rate		35.0%		34.0%
State income taxes, net of federal deduction		2.1%		4.7%
Permanent differences		-0.1%		10.6%
Change in valuation allowance		-37.0%		0.0%

		0.0%		49.3%

Note 9 – Business Combinations

Completion of Merger

On November 2, 2015, the Company completed its merger (the “Merger”) with Medytox Solutions, Inc. (“Medytox”). In connection with the Merger, (i) each share of common stock of Medytox was converted into the right to receive about 0.4096 shares of common stock of CollabRx, (ii) each share of Series B Preferred Stock of Medytox was converted into the right to receive one share of a newly-authorized Series B Convertible Preferred Stock of CollabRx, and (iii) each share of Series E Convertible Preferred Stock of Medytox was converted into the right to receive one share of a newly-authorized Series E Convertible Preferred Stock of CollabRx.

Holders of CollabRx equity prior to the closing of the Merger (including all outstanding CollabRx common stock and all restricted stock units, options and warrants exercisable for shares of CollabRx common stock) held 10% of CollabRx’s common stock immediately following the closing of the Merger, and holders of Medytox equity prior to the closing of the Merger (including all outstanding Medytox common stock and all outstanding options exercisable for shares of Medytox common stock, but less certain options that were cancelled upon the closing pursuant to agreements between Medytox and such optionees) held 90% of CollabRx’s common stock immediately following the closing of the Merger, in each case on a fully diluted basis, provided, however, outstanding shares of the newly designated Series B Convertible Preferred Stock and Series E Convertible Preferred Stock, certain outstanding convertible promissory notes exercisable for CollabRx common stock after the closing and certain option grants expected to be made at or immediately following the closing of the Merger are excluded from such ownership percentages.

Also in connection with the Merger: (i) each of James Karis, Jeffrey M. Kraus and Carl Muscari resigned from CollabRx’s Board of Directors; (ii) each of Seamus Lagan, Christopher Diamantis, Benjamin Frank, Michael L. Goldberg and Robert Lee was appointed to serve on CollabRx’s Board of Directors; and (iii) Thomas R. Mika was appointed Chairman of the Board, Seamus Lagan was appointed Chief Executive Officer and President, Jason Adams was appointed Chief Financial Officer, and Sebastian Sainsbury was appointed Secretary.

Prior to the closing of the Merger, the Company amended its certificate of incorporation to effect a 1-for-10 reverse split and to change its name to Rennova Health, Inc. On November 3, 2015, the common stock of Rennova commenced trading on the Nasdaq Capital Market under the symbol RNVA. Immediately after the consummation of the Merger, Rennova had 13,750,010 shares of common stock, 5,000 shares of Series B Convertible Preferred Stock and 45,000 shares of Series E Convertible Preferred Stock issued and outstanding.

The transaction was accounted for as a reverse acquisition. As such, the prior period equity amounts have been retroactively restated to reflect the equity instruments of the legal acquirer. The consideration given for CollabRx totals $12,289,297, consisting of the fair value of common stock and warrants exchanged in the merger transaction.

The Company acquired the remaining 49.5% of Biohealth in the three months ended March 31, 2015. The Company accounted for the assets, liabilities and ownership interests in accordance with the provisions of FASB ASC 805 “Business Combinations”. As such, the recorded assets and liabilities acquired have been recorded at fair value and any difference in the net asset values and the consideration given was recorded as goodwill.

RENNOVA HEALTH, INC.

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 10 – Commitments and Contingencies

Legal Matters

During the course of business, litigation commonly occurs. From time to time, the Company may be a party to litigation matters involving claims against the Company. The Company operates in a highly regulated industry which may inherently lend itself to legal matters. Management is aware that litigation has associated costs and that results of adverse litigation verdicts could have a material effect on the Company's financial position or results of operations. Management, in consultation with legal counsel, has addressed known assertions and predicted unasserted claims below.

Epinex Diagnostics Laboratories, Inc. (“Epinex”) has been sued in a California state court by two former employees who allege that they were wrongfully terminated, as well as a variety of unpaid wage claims. The Company participated in formal mediation on February 25, 2016 in California.

In February 2016, the Company received notice that the Internal Revenue Service had placed a lien against Medytox Solutions, Inc. and its subsidiaries relating to unpaid 2014 taxes due, plus penalties and interest, totaling $4,964,020. The Company paid $100,000 toward its 2014 tax liability in March 2016. The Company filed its 2015 Federal tax return on March 15, 2016. The 2015 return and the accompanying election to carryback the reported net operating losses, which was filed in April 2016, should permit the Company to have the lien lifted when reviewed and processed by the IRS.

RENNOVA HEALTH, INC.

Notes to Condensed Consolidated Financial Statements

(unaudited)

Note 11 – Segment Reporting

Selected financial information for the Company’s operating segments is as follows:

	Three Months Ended March 31,
	2016			2015
Net revenues - External
Clinical Laboratory Operations	$	1,465,137		$	13,499,803
Supportive Software Solutions		230,026			148,979
Decision Support and Informatics Operations		183,650			–
Corporate		–			–
Eliminations		–			–
	$	1,878,813		$	13,648,782
Net revenues - Inter Segment
Clinical Laboratory Operations	$	–		$	–
Supportive Software Solutions		296,348			384,108
Decision Support and Informatics Operations		–			–
Corporate		–			–
Eliminations		–			–
	$	296,348		$	384,108
Income (loss) from operations
Clinical Laboratory Operations	$	(2,650,540	)	$	5,065,421
Supportive Software Solutions		(1,313,313	)		(1,357,989	)
Decision Support and Informatics Operations		(881,566	)		–
Corporate		(1,952,437	)		(1,521,117	)
Eliminations		33,660			28,246
	$	(6,764,196	)	$	2,214,561
Depreciation and amortization
Clinical Laboratory Operations	$	581,101		$	447,325
Supportive Software Solutions		164,428			160,356
Decision Support and Informatics Operations		14,527			–
Corporate		875			1,358
Eliminations		(33,661	)		(28,246	)
	$	727,270		$	580,793
Capital expenditures
Clinical Laboratory Operations	$	16,885		$	187,885
Supportive Software Solutions		2,117			25,257
Decision Support and Informatics Operations		–			–
Corporate		–			–
Eliminations		–			–
	$	19,002		$	213,142

RENNOVA HEALTH, INC.

Notes to Condensed Consolidated Financial Statements

(unaudited)

	March 31,			December 31,
	2016			2015
Total assets
Clinical Laboratory Operations	$	13,357,738		$	15,152,583
Supportive Software Solutions		2,677,943			2,896,473
Decision Support and Informatics Operations		3,714,571			4,307,053
Corporate		9,046,263			12,711,284
Eliminations		(6,327,245	)		(7,095,520	)
	$	22,469,270		$	27,971,873

Note 12 – Subsequent Events

In April 2016, the Company repaid $2,250,000 of the $3,000,000 then outstanding under the D&D note from proceeds of the prepaid forward purchase contract discussed above. This note was convertible into the Company’s Common Stock at a 25% discount to the trailing ten day average closing price at any time prior to the repayment. As such, the Company elected to repay a portion of the note prior to its maturity date.

The Company has evaluated subsequent events through the date the financial statements were issued and filed with SEC. The Company has determined that there are no other events that warrant disclosure or recognition in the financial statements.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

SPECIAL NOTE CONCERNING FORWARD-LOOKING STATEMENTS

Certain statements made in this Form 10-Q are "forward-looking statements" (within the meaning of the Private Securities Litigation Reform Act of 1995) regarding the plans and objectives of management for future operations. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The forward-looking statements included herein are based on current expectations that involve numerous risks and uncertainties. The Company's plans and objectives are based, in part, on assumptions involving the continued expansion of business. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of the Company. Although the Company believes its assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove to be inaccurate and, therefore, there can be no assurance the forward-looking statements included in this report will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by the Company or any other person that the objectives and plans of the Company will be achieved.

The forward-looking statements included in this Form 10-Q and referred to elsewhere are related to future events or our strategies or future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may," "should," "believe," "anticipate," "future," "potential," "estimate," "encourage," "opportunity," "growth," "leader," "expect," "intend," "plan," "expand," "focus," "through," "strategy," "provide," "offer," "allow," "commitment," "implement," "result," "increase," "establish," "perform," "make," "continue," "can," "ongoing," "include" or the negative of such terms or comparable terminology. All forward-looking statements included in this Form 10-Q are based on information available to us as of the filing date of this report, and the Company assumes no obligation to update any such forward-looking statements, except as required by law. Our actual results could differ materially from the forward-looking statements.

Important factors that might cause our actual results to differ materially from the results contemplated by the forward-looking statements are contained in the “Risk Factors” section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2015 and in our subsequent filings with the Securities and Exchange Commission. The following discussion of our results of operations should be read together with our financial statements and related notes included elsewhere in this report.

Company Overview

Rennova Health, Inc. (“Rennova” or the “Company”) is a provider of diagnostics and supportive software solutions to healthcare providers. Through continued research and development of our diagnostics testing services and an ever-expanding group of strategic and interoperable software solutions that work in unison to empower customers, we aspire to create an efficient, effective single source solution and service for healthcare providers, their patients and individuals. We believe that our approach will benefit from a more sustainable relationship and the capture of multiple revenue streams from the same customer.

Our Services

Rennova is a healthcare enterprise that delivers products and services including laboratory diagnostics, healthcare technology solutions, and revenue cycle management and intends to provide financial services, to medical providers.

Its principal line of business to date is clinical laboratory blood and urine testing services, with a particular emphasis in the provision of urine drug toxicology testing to physicians, clinics and rehabilitation facilities in the United States. Rennova understands the challenges faced by today’s healthcare providers to adopt paper free and interoperable systems and in response to market demand for solutions, has responded strategically by expanding our offering of services to include a full suite of clinical laboratory services. The drug and alcohol rehabilitation and pain management sectors provide an existing and sizable target market, where the need for our services already exists and opportunity is being created by a continued secular growth and need for compliance.

We have recently added genetic testing, specifically pharmacogenetic testing, to our menu of services. Genetic testing represents a rapidly expanding segment of the diagnostics market worldwide. Growing incidence of genetic diseases present new opportunities for genetic testing. The global market for genetic testing is forecast to reach $2.2 billion by 2017. Increasing knowledge about the potential benefits of genetic testing is one of the prime reasons for the growth of the market. Advancements in the genetic testing space, an aging population and a subsequent rise in the number of chronic diseases, and increasing incidence of cancer cases are the other factors propelling growth in the genetic testing market.

Primary revenue generating activity in this market revolves around DNA profiling aimed at better understanding the predisposition for diseases and possible adverse reactions that may occur with available and/or under clinical development, drugs. Rising importance of early infection detection and prevention together with growing demand of DNA tests in pharmacogenomics or cancer genetic testing is a significant factor responsible for the anticipated growth.

The Company owns and operates the following products and services, to support its business objectives and to enable it to offer the services to its customers:

Medytox Diagnostics

Through its coast to coast CLIA certified clinical laboratories, Rennova offers toxicology, clinical pharmacogenetics and esoteric testing. Rennova seeks to provide these testing services with superior logistics and specimen integrity, competitive turn-around times and unparalleled customer service.

Advantage software

Advantage is a proprietary HIPAA compliant software developed to eliminate the need for paper requisitions by providing an easy to use and efficient web-based system that lets you securely place lab orders, track samples and view test reports in real time, all with a few simple clicks from any web-enabled laptop, notepad or smart phone.

Clinlab

A customized web-enabled laboratory information management solution that scales from small physician-operated labs to large clinical reference laboratories.

Medical Mime

Medical Mime offers an optimized Electronic Health Record (“EHR”) for substance abuse and behavioral health providers, a dictation-based ambulatory EHR for physician practices and advanced transcription services.

CollabRx

CollabRx offers interpretation and decision support solutions that enhance cancer diagnoses and treatment through actionable data analytics and reporting for oncologists and their patients.

Medical Billing Choices (“MBC”)

MBC enhances revenue cycle management by utilizing tools designed to improve documentation and collect information, driving faster reimbursement with fewer denied claims.

Platinum Financial Solutions

Platinum Financial Solutions seeks to provide financial solutions in the form of loans to physician practices collateralized by their accounts receivable or through the acquisition of their qualifying accounts receivable at a discounted value.

Recent Events

On March 18, 2014, the Company, pursuant to a stock purchase agreement, purchased all of the outstanding stock of Clinlab, Inc. (“Clinlab”). Clinlab develops and markets laboratory information management systems.

On May 9, 2014, the Company formed Medical Mime, Inc. (“Mime”), a Florida corporation, as a wholly-owned subsidiary. On May 23, 2014, Mime purchased certain net assets, primarily consisting of software, of GlobalOne Information Technologies, LLC (“GlobalOne”). GlobalOne developed software and provided services for the Electronic Records Management (“ERM”) segment of the medical industry.

On August 26, 2014, the Company purchased all of the outstanding stock of Epinex Diagnostics Laboratories, Inc. (“Epinex”), a California corporation. Epinex is a clinical laboratory in Tustin, California.

On June 1, 2015, the Company entered into a convertible loan and security agreement with Epinex Diagnostics, Inc., pursuant to which the Company agreed to provide advances to Epinex Diagnostics, Inc. of up to $637, 210. Under the agreement, the Company is entitled to 15% annual interest on the advances.

On November 2, 2015, pursuant to the terms of the Agreement and Plan of Merger, dated as of April 15, 2015, by and among CollabRx, Inc. (“CollabRx”), CollabRx Merger Sub, Inc. (“Merger Sub”), a direct wholly-owned subsidiary of CollabRx formed for the purpose of the merger, and Medytox Solutions, Inc. (“Medytox”), Merger Sub merged with and into Medytox, with Medytox as the surviving company and a direct, wholly-owned subsidiary of CollabRx (the “Merger”). Prior to closing, the Company amended its certificate of incorporation to effect a 1-for-10 reverse stock split and to change its name to Rennova Health, Inc. In connection with the Merger, (i) each share of common stock of Medytox was converted into the right to receive 0.4096377408003329 shares of common stock of the Company, (ii) each share of Series B Preferred Stock of Medytox was converted into the right to receive one share of a newly-authorized Series B Convertible Preferred Stock of the Company, and (iii) each share of Series E Convertible Preferred Stock of Medytox was converted into the right to receive one share of a newly-authorized Series E Convertible Preferred Stock of the Company. This transaction was accounted for as a reverse merger in accordance with Generally Accepted Accounting Policies.

On December 30, 2015, the Company issued Common Stock, Preferred Stock and warrants in a public offering. The offering raised approximately $10 million in gross proceeds.

On April 26, 2016, the Company was notified by Nasdaq that the stockholders’ equity balance reported on its Form 10-K for the year ended December 31, 2015 fell below the $2,500,000 minimum requirement for continued listing under the Nasdaq Capital Market’s Listing Rule 5550(b)(1) (the “Equity Rule”). As of December 31, 2015, the Company’s stockholder’s equity balance was $(1,193,799). In accordance with the Equity Rule, the Company has until June 10, 2016 to prepare and submit a plan to Nasdaq outlining how it intends to regain compliance. If the plan is accepted, the Company can be granted up to 180 calendar days from April 26, 2016 to evidence compliance. There can be no guarantee that the Company will be able to regain compliance with the Equity Rule or that its plan will be accepted by Nasdaq.

Results of Operations

We have three operating segments 1) Clinical Laboratory Operations, 2) Supportive Software Solutions, and 3) Decision Support and Informatics Operations. We present our discussion of results of operations by segment below.

Three months ended March 31, 2016 compared to three months ended March 31, 2015

The following table presents key financial and operating metrics for our Clinical Laboratory Operations segment:

	Three Months Ended March 31,
	2016			2015		Change			%
Financial Results:
Net revenues	$	1,465,137		$	13,499,803	$	(12,034,666	)		-89.1%
Operating expenses:
Direct costs of revenue		454,279			4,027,561		(3,573,282	)		-88.7%
General and administrative		2,490,181			2,777,275		(287,094	)		-10.3%
Sales and marketing expenses		590,116			1,182,221		(592,105	)		-50.1%
Impairment of goodwill and intangible assets		–			–		–			NM
Depreciation and amortization		581,101			447,325		133,776			29.9%

(Loss) income from operations	$	(2,650,540	)	$	5,065,421	$	(7,715,961	)		-152.3%

Key Operating Measures - Revenues:
Insured tests performed		60,857			415,573		(354,716	)		-85.4%
Revenue per insured test	$	24.08		$	32.48	$	(8.41	)		-25.9%
Revenue recognition percent of gross billings		20.0%			28.0%		-8.0%

Key Operating Measures - Direct Costs:
Total samples processed		5,580			20,600		(15,020	)		-72.9%
Direct costs per sample	$	81.41		$	195.51	$	(114.10	)		-58.4%

The decline in net revenues related primarily to (a) a decrease in the net recovery rate of revenues from 28% of gross billings to insurance carriers to 20% of gross billings to insurance carriers and (b) the 85.4% decline in insured test volume. The decrease in the net recovery rate resulted in a decrease in net revenues of $3.9 million. The decrease in insured test volume resulted in a decrease in net revenues of $8.2 million.

The decline in direct costs of revenue resulted from (a) the transition of a significant portion of our testing from external reference labs to internal processing, resulting in a 58.4% decrease in direct costs per sample and (b) the 72.9% decline in total samples processed. The decline in direct cost per sample resulted in a $0.6 million decrease in direct costs of revenues while the decline in total samples processed resulted in a $2.9 million decrease in direct costs of revenues.

The decline in general and administrative costs resulted primarily from a decrease in the amounts charged by our Supportive Software Solutions group to our Clinical Laboratory Operations group for services provided.

The decline in sales and marketing expenses related primarily to the decline in commissionable collections related to the decline in net revenues.

The increase in depreciation and amortization relates primarily to the expansion of our Riviera Beach, Florida laboratory and improvements required to transition a significant portion of our testing from external reference labs to internal processing.

The following table presents key financial metrics for our Supportive Software Solutions segment:

	Three Months Ended March 31,
	2016			2015			Change			%
Net revenues	$	526,374		$	533,087		$	(6,713	)		-1.3%
Operating expenses:
Direct costs of revenue		83,973			3,712			80,261			2162.2%
General and administrative		1,590,001			1,727,008			(137,007	)		-7.9%
Bad debt		1,285			–			1,285			NM
Depreciation and amortization		164,428			160,356			4,072			2.5%

Loss from operations	$	(1,313,313	)	$	(1,357,989	)	$	44,676			-3.3%

The 1.3% decrease in net revenues from 2015 relates primarily to a $0.1 million decline in the amounts charged by our Supportive Software Solutions group to our Clinical Laboratory Operations group for services provided, partially offset by revenues generated from the launch of our electronic health records product, Medical Mime, into the rehab sector in the fourth quarter of 2015.

The decrease in general and administrative expenses relates primarily to movement of a significant portion of our development activities from contracted labor to internal personnel.

The increase in depreciation and amortization relates primarily to the purchase of additional technology assets required to support the launch of our electronic health records product into the rehab sector and for support of general corporate requirements.

The following table presents key financial metrics for our Decision Support and Informatics Operations segment:

	Three Months Ended March 31,
	2016			2015		Change			%
Net revenues	$	183,650		$	–	$	183,650			NM
Operating expenses:
Direct costs of revenue		25,948			–		25,948			NM
General and administrative		218,650			–		218,650			NM
Sales and marketing expenses		283,323			–		283,323			NM
Engineering		522,768			–		522,768			NM
Depreciation and amortization		14,527			–		14,527			NM

Loss from operations	$	(881,566	)	$	–	$	(881,566	)		NM

All changes versus the prior year relate to the acquisition of CollabRx, Inc. in November 2015 and the resulting creation of the Decision Support and Informatics Operations segment.

The following table presents key financial metrics for our Corporate group:

	Three Months Ended March 31,
	2016			2015			Change			%
Operating expenses:
General and administrative	$	1,951,562		$	1,519,759		$	431,803			28.4%
Depreciation and amortization		875			1,358			(483	)		-35.6%

Loss from operations	$	(1,952,437	)	$	(1,521,117	)	$	(431,320	)		28.4%

The increase in general and administrative costs relates primarily to the expansion of our management team.

The following table presents consolidating operating income and other income and expense items for the Company:

	Three Months Ended March 31,
	2016			2015			Change			%
Income (loss) from operations:
Clinical Laboratory Operations	$	(2,650,540	)	$	5,065,421		$	(7,715,961	)		-152.3%
Supportive Software Solutions		(1,313,313	)		(1,357,989	)		44,676			-3.3%
Decision Support and Informatics Operations		(881,566	)		–			(881,566	)		NM
Corporate		(1,952,437	)		(1,521,117	)		(431,320	)		28.4%
Eliminations		33,660			28,246			5,414			19.2%

(Loss) income from operations		(6,764,196	)		2,214,561			(8,978,757	)		-405.4%

Interest expense		(1,013,413	)		(505,101	)		(508,312	)		100.6%
Other income		3,533,598			275,049			3,258,549			1184.7%

(Loss) income before income taxes		(4,244,011	)		1,984,509			(6,228,520	)		-313.9%

Income tax (benefit) expense		–			977,500			(977,500	)		-100.0%

Net (loss) income	$	(4,244,011	)	$	1,007,009		$	(5,251,020	)		-521.4%

The increase in interest expense relates primarily to increased borrowings in the first quarter of 2016 and an increase of $0.5 million in non-cash amortization of debt discounts.

Other income relates to items that are generally non-recurring in nature. Therefore, inter-period comparisons are not meaningful. For the three months ended March 31, 2016, other income was comprised of a $3.4 million unrealized gain on derivative instruments related to the change in valuation associated with our various floating price convertible debt instruments and warrants. For the three months ended March 31, 2015, other income was comprised of a $0.3 million gain on a legal settlement.

For the three months ended March 31, 2016, our effective tax rate was 0.0% versus 49.3% for the same period of 2015. The decrease in our effective tax rate relates primarily to of a 100% valuation allowance against our net deferred tax assets in the first quarter of 2016.

Liquidity and Capital Resources

Overview

The Company historically has utilized cash generated from operations and various credit facilities to fund working capital needs, acquisitions and capital expenditures. Future cash needs for working capital, acquisitions and capital expenditures may require management to seek additional equity or obtain additional credit facilities. The sale of additional equity could result in additional dilution to the Company's stockholders. A portion of the Company's cash may be used to acquire or invest in complementary businesses or products or to obtain the right to use complementary technologies. From time to time, in the ordinary course of business, the Company evaluates potential acquisitions of such businesses, products or technologies.

For the three months ended March 31, 2016 and 2015, we funded our operations primarily through borrowings from third parties. Our principal use of funds during the three months ended March 31, 2016 and 2015 has been for operating activities, payments on borrowings, additions to property and equipment, dividends to former Medytox Preferred B shareholders (during the three months ended March 31, 2015) and general corporate expenses. Management believes that based on the current level of operations, cash flow from operations and financing activities, the Company will have to secure additional funding in order to have sufficient liquidity to fund anticipated expenses, tax obligations and other commitments for the next twelve months.

Liquidity and Capital Resources during the three months ended March 31, 2016 and 2015

The following table presents our capital resources as of March 31, 2016 and December 31, 2015:

	March 31,			December 31,
	2016			2015			Change
Cash	$	4,900,806		$	8,833,230		$	(3,932,424	)
Working capital	$	(3,017,985	)	$	4,218,687		$	(7,236,672	)
Total debt	$	12,342,015		$	8,306,817		$	4,035,198
Total equity	$	(5,428,500	)	$	(1,193,799	)	$	(4,234,701	)

The following table presents the major sources and uses of cash for the three months ended March 31, 2016 and 2015:

	Three Months Ended March 31,
	2016			2015			Change
Cash used in operations	$	(6,990,241	)	$	(3,792,233	)	$	(3,198,008	)
Cash used in investing activities		(19,002	)		(213,142	)		194,140
Cash provided by financing activities		3,076,819			2,249,634			827,185

Net change in cash	$	(3,932,424	)	$	(1,755,741	)	$	(2,176,683	)

The increase in cash used in operations from the three months ended March 31, 2015 the three months ended March 31, 2015 is presented in the following table:

	Three Months Ended March 31,
	2016			2015			Change
Net (loss) income	$	(4,244,011	)	$	1,007,009		$	(5,251,020	)
Non-cash adjustments to income		(2,006,347	)		7,476,235			(9,482,582	)
Change in accounts receivable		1,096,357			(12,843,394	)		13,939,751
Change in accounts payable and accrued expenses		(1,608,362	)		117,405			(1,725,767	)
Change in income tax assets and liabilities		(101,015	)		506,669			(607,684	)
Change in other assets and liabilities		(126,863	)		(56,157	)		(70,706	)

Cash from operations	$	(6,990,241	)	$	(3,792,233	)	$	(3,198,008	)

The decline in net income is discussed in results of operations above. The decrease in non-cash adjustments to revenue relates primarily to a $6.5 million decrease in allowances for bad debts.

The improvement in accounts receivable performance relates primarily to a decrease of $6.5 million in allowance for bad debts as well as improved collections versus revenues in the three months ended March 31, 2016 versus the same period of 2015.

The deterioration of accounts payable performance relates primarily to catch-up payments on accounts payable that were outstanding at December 31, 2015, versus little such activity in the three months ended March 31, 2015.

The minimal change in income tax assets and liabilities for the three months ended March 31, 2016 relates to the accrual of a 100% valuation allowance on our net deferred tax assets.

The decrease in capital expenditures relates primarily to the completion of the build out of our Riviera Beach, Florida laboratory in 2015.

The increase in cash from financing activities relates primarily to the placement of a $5,000,000 note payable relating to the prepaid forward purchase contract during the three months ended March 31, 2016. For a description of our various debt instruments and specific transactions, see Note 4 – Notes Payable to the Condensed Consolidated Financial Statements.

Going Concern

The Company’s consolidated financial statements and management’s discussion and analysis of financial condition and results of operations are prepared using Generally Accepted Accounting Principles applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, the Company has recently accumulated significant losses and has negative cash flows from operations, which raise substantial doubt about its ability to continue as a going concern. Management's plans with respect to alleviating the adverse financial conditions that caused management to express substantial doubt about the Company’s ability to continue as a going concern are as follows:

In order to support the Company’s continued operation, the Company received $5,000,000 from pledging certain of its accounts receivable as collateral to a prepaid forward purchase contract. The Company is also entitled to $2,516,028 in income tax refunds, the claim for which was filed with the IRS in early April 2016. There can be no assurance as to the timing of the receipt of the income tax refunds for which the Company has filed.

Critical Accounting Policies

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make a number of estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Such estimates and assumptions affect the reported amounts of revenues and expenses during the reporting period. We base our estimates on historical experiences and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions and conditions. We continue to monitor significant estimates made during the preparation of our financial statements. On an ongoing basis, we evaluate estimates and assumptions based upon historical experience and various other factors and circumstances. We believe our estimates and assumptions are reasonable in the circumstances; however, actual results may differ from these estimates under different future conditions.

See Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and Note 2, “Summary of Significant Accounting Policies” in our audited consolidated financial statements as of and for the year ended December 31, 2015, included in our Annual Report on Form 10-K/A filed with the U.S. Securities and Exchange Commission (“SEC”) on May 17, 2016.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Not applicable

Item 4. Controls and Procedures.

(a)

Evaluation of Disclosure Controls and Procedures

In connection with the preparation of this Quarterly Report on Form 10-Q, an evaluation was carried out by the Company's management, with the participation of the principal executive officer and the principal financial officer, of the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 ("Exchange Act")) as of March 31, 2016. Disclosure controls and procedures are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to management, including the chief executive officer and the chief financial officer, to allow timely decisions regarding required disclosures.

Based on that evaluation, the Company's management concluded, as of the end of the period covered by this report, that the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) were not effective. In connection with such evaluation, management concluded that the material weakness in internal control over financial reporting identified in our Form 10-K for the year ended December 31, 2015 continued to exist, and as such our disclosure controls and procedures were not effective as of March 31, 2016. Insufficient staffing and accounting processes and procedures led to a lack of contemporaneous documentation supporting the accounting for certain transactions. The Company is in the process of taking the following steps to remediate the material weakness: (i) increasing the staffing of its internal accounting department, (ii) engaging outside independent consultants to assist in the analysis of complex accounting transactions, and (iii) implementing enhanced documentation procedures to be followed by the internal accounting department and outside independent consultants.

Notwithstanding such material weakness, management believes that the condensed consolidated financial statements included in this Form 10-Q fairly present in all material respects the Company's financial condition, results of operations and cash flows for the periods and dates presented.

(b)

Changes in Internal Control over Financial Reporting

Except as set forth above, there were no changes in our internal control over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings.

In February 2016, the Company received notice that the Internal Revenue Service had placed a lien against Medytox Solutions, Inc. and its subsidiaries relating to unpaid 2014 taxes due, plus penalties and interest, totaling $4,964,020. The Company paid $100,000 toward its 2014 tax liability in March 2016. The Company filed its 2015 Federal tax return on March 15, 2016. The 2015 return and the accompanying election to carryback the reported net operating losses should permit the Company to have the lien lifted.

Item 1A. Risk Factors.

In addition to the other information set forth in this report, you should carefully consider the risk factors discussed in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2015 which could materially affect our business, financial condition, or future results. There have been no material changes to the risk factors previously disclosed in our 2015 Form 10-K.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

On March 8, 2016, the Company issued 13,300 shares of Common Stock, $0.01 par value, to a consultant for services rendered.

On March 14, 2016, the Company issued 256,666 shares of Common Stock, $0.01 par value, to its financial adviser in connection with the consummation of the Merger.

These securities were not registered under the Securities Act of 1933, as amended (the “Securities Act”), but were issued in reliance upon the exemption from registration provided by Section 4(2) of the Securities Act as a transaction by an issuer not involving a public offering.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

Item 6. Exhibits

Exhibit 10.1	Consulting Agreement, dated August 1, 2015, between Medytox Solutions, Inc. and Monarch Capital, LLC
Exhibit 31.1	Rule 13a-14(a) Certification by the Principal Executive Officer
Exhibit 31.2	Rule 13a-14(a) Certification by the Principal Financial Officer
Exhibit 32.1	Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*
Exhibit 32.2	Certification by the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*
Exhibit 101.INS	XBRL Instance Document
Exhibit 101.SCH	XBRL Schema Document
Exhibit 101.CAL	XBRL Calculation Link base Document
Exhibit 101.DEF	XBRL Definition Link base Document
Exhibit 101.LAB	XBRL Label Link base Document
Exhibit 101.PRE	XBRL Presentation Link base Document

____________________

*Furnished herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		RENNOVA HEALTH, INC.

Date: May 17, 2016		By: /s/ Seamus Lagan
		Seamus Lagan
		Chief Executive Officer (Principal Executive Officer)

Date: May 17, 2016

By: /s/ Jason P. Adams

Jason P. Adams

Chief Financial Officer

(Principal Financial Officer)

EX-10.112 2 rennova_10q-ex1001.htm CONSULTING AGREEMENT

Exhibit 10.1

MEDYTOX SOLUTIONS, INC. AND MONARCH CAPITAL
CONSULTING AGREEMENT

THIS AGREEMENT is between Medytox Solutions, Inc. (hereinafter referred to as "Medytox or Company"), whose address is 400 S. Australian Avenue, West Palm Beach, Fl. 33401 and MONARCH CAPITAL, LLC., whose address is 6161 NW 31 Way, Fort Lauderdale, Florida, 33309 (hereinafter referred to as the "Consultant") and is deemed active on the date executed herein.

WHEREAS, Medytox is in the business of providing laboratory services, medical billing services, financial services, research, development, engineering, design, operations, ownership, licensing and management of various cutting edge technologies in the laboratory services, medical software, financial services fields, etc. and

WHEREAS, the Consultant is in the business of assisting Medytox in providing business and financial advice including but not limited to; strategic business planning, market entry services, outreach and education services, marketing, sales, political strategy, relationship management, contract and document review, consulting with Medytox lawyers and accountants concerning its public company status and compliance, etc.

WHEREAS, the Consultant may, during the period of time covered by this Agreement, present to the Company one or more plans to achieve the Company's goals of sales of intellectual property, services, equipment, and various technologies, and emplacement of Company equipment as it relates to the technology, and also may identify and introduce, educate or refer potential funding sources, clients, end users, and/or potential business contacts/strategic partners to the Company; recommend potential business strategies as well as additional consultants or service providers and cause revenue to be created for Company by Consultants direct, indirect or referral efforts; and

WHEREAS, the Company recognizes that the Consultant is not in the business of stock brokerage, providing investment advice, engaging in activities which require registration under either the Securities Act of 1933 (hereinafter "the Act") or the Securities and Exchange Act of 1934 (hereinafter "the Exchange Act"), underwriting, banking, acting as an insurance Company, nor does it offer services to the Company which may require regulation under federal or state securities laws; and

WHEREAS, the parties agree, after having a complete understanding of the services desired and the services to be provided, that the Company desires to retain Consultant to provide such assistance through its services for the Company, and the Consultant is willing to provide such services to the Company;

NOW, THEREFORE, in consideration of the mutual covenants and promises contained herein, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:

1. Duties and Involvement.

The Company hereby engages Consultant to provide one or more of the services previously described herein, or plans (the "Plan") which lead to the acquisition of clients who purchase, lease, own, acquire, or use the technology or services which the Company wishes to proliferate for fee based services, and for coordination in executing the agreed-upon plan, for using various business services as agreed by both parties. The plans may include, but not by way of limitation, the following services: consult with the Company's management concerning securing clients, expand investor/user base, strategic business planning, broker relations, attendance at conventions and trade shows, consult of mergers with companies, review and assistance in updating a business plan, review and advise on the capital structure for the Company, propose or work with Company's legal counsel and auditors, assist in the development of an acquisition profile and structure, recommend financing alternatives and sources, marketing surveys, client and relationship management, market entry services, acquisition and execution of various political assistance and or selection of operatives (enterprise, private, municipal or sovereign), and/or consult on corporate finance, investment banking issues, legal issues, and or any other element required of consultant in the successful implementation of this undertaking not directly addressed herein as requested by Company and agreed to by Consultant.

The Company agrees that Consultant's work is unique and invaluable to the direction and development of the Company's business and recognizes that although the introductory consulting work is done during a specific time period, the tangible effects as a result of Consultant's work may last years and create multiple fee paid events as a result of the initial efforts either directly or indirectly and may last many years past the term and scope of this agreement. As such, because there is no specific limit to the value of the services provided by Consultant, Company agrees to pay Consultant as defined for services rendered.

2. Relationship Among the Parties.

Consultant acknowledges that it is not an officer, or agent of the Company, it is not, and will not, be responsible for any management decisions on behalf of the Company, and may not commit the Company to any action not expressly approved by the Company. The Company represents that the consultant does not have, through stock ownership or otherwise, the power neither to control the Company, nor to exercise any dominating influences over its management.

Consultant understands and acknowledges that this Agreement shall not create or imply any agency/broker relationship among the parties, and Consultant will not commit the Company in any manner except when a commitment has been specifically authorized in writing by the Company. The Company and the Consultant agree that the relationship among the parties shall be that of independent contractor.

3. Effective Date, Authority, Term and Termination.

This Agreement shall be effective on and will continue until the date of August 31 2016, a term of one (1) year This Agreement can be modified and extended only by mutual agreement in writing. The signing officer of Company hereby warrants that he has taken all steps necessary and is authorized to execute this agreement on behalf of Company.

4. Option to Renew and Extend.

Company may renew or amend this Agreement by providing written notice to Consultant by negotiating new terms at any time prior to the expiration hereof upon mutual acceptance of terms and conditions by Consultant which shall be accepted by both parties in writing.

5. Compensation and Payment of Expenses.

The Company agrees to pay the Consultant as follows:

In full by check or wire transfer of funds within 5 days of the beginning of each month with first payment due at signing.

Payment terms and conditions are defined in Appendix A.

Company shall have no other obligation to Consultant for payment, excepting the obligation for additional compensation as contained herein.

Company agrees and shall pay for all costs and expenses incurred associated with its working with Consultant and its representatives, including lodging, meals and travel as necessary upon prior approval.

6. Client Service, Market Entry Services, and Public and Political Representation.

The Company represents and warrants that it has or will provide Consultant with access to all necessary information available to the Company concerning its condition, financial and otherwise, its management, its business and its prospects and all other information of interest to any qualified client as Consultant desires and will continue to update Consultant on any and all changes in status.

The Consultant represents that neither it nor its officers, directors, or employees has been or is not subject to any disciplinary action by either the National Association of Securities Dealers or the Securities and Exchange Commission by virtue of any violations of their rules and regulations and that to the best of its knowledge neither is its affiliates nor subcontractors subject to any such disciplinary action.

7. Consultant Services Not Exclusive to Company.

Consultant shall devote such of its time and effort necessary to the discharge of its duties hereunder. The Company acknowledges that Consultant is engaged in other business activities, and that it will continue such activities during the term of this Agreement. Consultant shall not be restricted from engaging in other business activities during the term of this Agreement.

8. Confidentiality.

Consultant acknowledges that it may have access to confidential information regarding the Company and its business. Consultant agrees that it will not, during or subsequent to the term of this Agreement, divulge, furnish or make accessible to any person (other than with the written permission of the Company) any knowledge or information or plans of the Company with respect to the Company or its business, including, but not by way of limitation, the products of the Company, whether in the concept or development stage, or being marketed by the Company on the effective date of this Agreement or during the term hereof. Consultant acknowledges the unique and confidential nature of this Agreement and agrees to nondisclosure of same under any and all circumstances excepting those in which a court of proper jurisdiction shall insist upon disclosure. Consultant is obliged to obey all US and Brazilian laws in the execution of its duties.

9. Broker Dealer

The Company recognizes that the Consultant is not a broker or dealer as such terms are defined under the 1933 and 1934 Securities Act as well as any other State or any other regulations and promulgations interpreting or enforcing the terms of such acts, regulations or promulgations. As such the parties expressly acknowledge that all fees paid to Consultant hereunder constitute consulting fees for its strategic advice and not for raising capital for the Company; and that the services of Consultant described in this consulting agreement are not intended to engage Consultant to provide services as a broker or dealer of agent acting on behalf of the Company in any placement of securities.

Consultant shall engage in no negotiations on behalf of the Company, nor shall Consultant participate in discussions between any entity introduced by Consultant and the Company over infusion of capital into the Company. Consultant shall not act as a broker dealer in any way, and the parties acknowledge that Consultant is not licensed to do so. Consultant's only activity in this regard is to make the introduction to potential funding sources and nothing more. Consultant's compensation set forth herein is based solely on the introduction to the potential funding sources and all other services performed for Company. Each of these services in and of itself represents the full basis for Consultant's fee. As such because Consultant's work and potential introductions may develop relationships that last longer than the term of this contract, and as such these relationships and/or Consultant's advice may possibly lead to future opportunities for the Company without the Consultant being explicitly involved, the Company hereby agrees to pay the Consultant the full amount of this contract without exception on the date of its execution as per the payment schedule in Appendix "A". All payments are final and nonrefundable, without exception. Section11 is irrevocable and will survive past the termination date of this contract.

11. Indemnification.

Company agrees to indemnify and hold harmless the Consultant and its respective agents and employees, against any losses, claims, damages or liabilities, joint or several, to which either party, or any such other person, may become subject, insofar as such losses, claims, damages or liabilities (or actions, suits or proceedings in respect thereof) arise out of or are based upon any misleading/ untrue statement or alleged untrue statement of any material fact contained in technical, financial and/or sales information supplied to potential clients or their representatives, any registration statement, any preliminary prospectus, the prospectus, or any amendment or supplement thereto; or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading; and will reimburse the Consultant, or any such other person, for any legal or other expenses reasonably incurred by the Consultant, or any such other person, in connection with investigation or defending any such loss, claim, damage, liability, or action, suit or proceeding. Such reimbursement of attorney's fees shall be made promptly upon presentation of said invoices by Consultant to Company.

12. Miscellaneous Provisions

Section a Time. Time is of the essence of this Agreement.

Section b Presumption. This Agreement or any section thereof shall not be construed against any party due to the fact that said Agreement or any section thereof was drafted by said party.

Section c Computation of Time. In computing any period of time pursuant to this Agreement, the day of the act, event or default from which the designated period of time begins to run shall be included, unless it is a Saturday, Sunday or a legal holiday, in which event the period shall begin to run on the next day which is not a Saturday, Sunday or a legal holiday, in which event the period shall run until the end of the next day thereafter which is not a Saturday, Sunday or legal holiday.

Section d Titles and Captions. All article, section and paragraph titles or captions contained in this Agreement are for convenience only and shall not be deemed part of the context nor affect the interpretation of this Agreement.

Section e Pronouns and Plurals. All pronouns and any variations thereof shall be deemed to refer to the masculine, feminine, neuter, singular or plural as the identity of the Person or Persons may require.

Section f Further Action. The parties hereto shall execute and deliver all documents, provide all information and take or forbear from all such action as may be necessary or appropriate to achieve the purposes of this Agreement.

Section g Good Faith, Cooperation and Due Diligence. The parties hereto covenant, warrant and represent to each other good faith, complete cooperation, due diligence and honesty in fact in the performance of all obligations of the parties pursuant to this Agreement. All promises and covenants are mutual and dependent.

Section h Savings Clause. If any provision of this Agreement, or the application of such provision to any person or circumstance, shall be held invalid, the remainder of this Agreement, or the application of such provision to persons or circumstances other than those as to which it is held invalid, shall not be affected thereby.

Section I Assignment. This Agreement may not be assigned by the Consultant without the Company's consent and shall be binding upon any successors thereto.

Section j Jurisdiction/Venue & Attorney Fees. The parties agree that any dispute arising under this Agreement shall be heard in the federal or state courts sitting in the State of Florida. If any party employs counsel to enforce or interpret this Agreement, including the commencement of any legal preceding whatsoever (including insolvency, bankruptcy, arbitration, declaratory relief or other litigation), the prevailing party shall be entitled to recover its reasonable attorneys' fees and court costs. All parties hereby agree to submit to the personal jurisdiction as stated above.

Section k Notices. All notices required or permitted to be given under this Agreement shall be given in writing and shall be delivered, either personally or by express delivery service, to the party to be notified. Notice to each party shall be deemed to have been duly given upon delivery, personally or by courier (such as Federal Express or similar express delivery service), addressed to the attention of the officer at the address set forth heretofore, or to such other officer or addresses as either party may designate, upon at least ten (10) days' written notice, to the other party.

Section 1 Governing law. The Agreement shall be construed by and enforced in accordance with the laws of the State of Florida .

Section m Entire agreement. This Agreement contains the entire understanding and agreement among the parties. There are no other agreements, conditions or representations, oral or written, express or implied, with regard thereto. This Agreement may be amended only in writing signed by all parties.

Section n Waiver. A delay or failure by any party to exercise a right under this Agreement, or a partial or single exercise of that right, shall not constitute a waiver of that or any other right.

Section o Counterparts. This Agreement may be executed in duplicate counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same Agreement. In the event that the document is signed by one party and faxed to another the parties agree that a faxed signature shall be binding upon the parties to this agreement as though the signature was an original.

Section p Successors. The provisions of this Agreement shall be binding upon all parties, their successors and assigns.

Section q Counsel. The parties expressly acknowledge that each has been advised to seek separate counsel for advice in this matter and has been given a reasonable opportunity to do so.

Section r Accounting. Consultant shall have the right upon request to review all financial records of Company as it relates to any and all projects or the company's books and records themselves. Said records shall be produced within ten (10) days of any written request by Consultant.

Section s Termination. Company agrees to notify Consultant within 180 days prior to the termination date of the agreement of its intent to terminate this consulting agreement. Should Company not notify Consultant, then the agreement automatically renews for an additional one (1) year with a five (5%) increase in the then current monthly fee. Termination shall not cancel any obligations of Company to pay Consultant any fees or other revenue earned.

IN WITNESS WHEREOF, the parties hereto have executed and delivered this Agreement to be effective as of the day and year provided herein and have guaranteed to each party that they have the appropriate corporate authority to enter into said contract.

This agreement is executed on this date, 1 August 2015 by and between Monarch Capital, LLC and Medytox.

	CONSULTANT:
	MONARCH CAPITAL,LLC.

	By: /s/ Michael Goldberg
	Michael Goldberg, MANAGING DIRECTOR


	COMPANY:
	Medytox:

	By: /s/ Seamus Lagan
	Seamus Lagan, PRESIDENT AND CEO

MEDYTOX SOLUTIONS, INC. AND MONARCH CAPITAL
CONSULTING AGREEMENT

APPENDIX A

Definition of Consultant's right to be paid and amounts of agreed upon remuneration and fees for such services.

1. Terms of Payment

a. Consultant shall be paid the following amounts: $7,500.00 due at signing; first 90 day period-$12,500.00 per month, second 90 day period-$15,000.00 per month, 3^rd 90 day period- $17,500.00 per month, 4^th 90 day period- $20,000.00 per month. Payment shall be due as previously described herein within five (5) days of the beginning of each month.

EX-31.1 3 rennova_10q-ex3101.htm CERTIFICATION

EXHIBIT 31.1

CERTIFICATION OF

PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO RULE 13A-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

I, Seamus Lagan, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Rennova Health, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s), if any, and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s), if any, and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

Date: May 17, 2016	/s/ Seamus Lagan
	Chief Executive Officer (Principal Executive Officer)

EX-31.2 4 rennova_10q-ex3102.htm CERTIFICATION

EXHIBIT 31.2

CERTIFICATION OF

PRINCIPAL FINANCIAL OFFICER

PURSUANT TO RULE 13A-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

I, Jason P. Adams, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Rennova Health, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(a)

(b)

(c)

(d)

5.	The registrant’s other certifying officer(s), if any, and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent function):

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls over financial reporting.

Date: May 17, 2016	/s/ Jason P. Adams
	Chief Financial Officer (Principal Financial Officer)

EX-32.1 5 rennova_10q-ex3201.htm CERTIFICATION

EXHIBIT 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

In connection with this Quarterly Report of Rennova Health, Inc., a Delaware corporation (the “Company”), on Form 10-Q for the period ended March 31, 2016 as filed with the Securities and Exchange Commission (the “Report”), I, Seamus Lagan, Chief Executive Officer of the Company, certify, pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Sec. 1350), that to my knowledge:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: May 17, 2016

/s/ Seamus Lagan
Seamus Lagan Chief Executive Officer (Principal Executive Officer)

EX-32.2 6 rennova_10q-ex3202.htm CERTIFICATION

EXHIBIT 32.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

In connection with this Quarterly Report of Rennova Health, Inc., a Delaware corporation (the “Company”), on Form 10-Q for the period ended March 31, 2016 as filed with the Securities and Exchange Commission (the “Report”), I, Jason P. Adams, Chief Financial Officer of the Company, certify, pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Sec. 1350), that to my knowledge:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: May 17, 2016

/s/ Jason P. Adams
Jason P. Adams Chief Financial Officer (Principal Financial Officer)

EX-101.INS 7 rnva-20160331.xml XBRL INSTANCE FILE 0000931059 2015-12-31 0000931059 us-gaap:SeriesBPreferredStockMember 2016-03-31 0000931059 us-gaap:SeriesBPreferredStockMember 2015-12-31 0000931059 us-gaap:SeriesEPreferredStockMember 2016-03-31 0000931059 us-gaap:SeriesEPreferredStockMember 2015-12-31 0000931059 2016-05-09 0000931059 RNVA:SupportiveSoftwareSolutionsMember 2015-12-31 0000931059 RNVA:ClinicalLaboratoryOperationsMember 2016-01-01 2016-03-31 0000931059 RNVA:SupportiveSoftwareSolutionsMember 2016-01-01 2016-03-31 0000931059 us-gaap:IntersegmentEliminationMember 2016-01-01 2016-03-31 0000931059 RNVA:MedicalEquipmentMember 2016-03-31 0000931059 RNVA:MedicalEquipmentMember 2015-12-31 0000931059 us-gaap:EquipmentMember 2016-03-31 0000931059 us-gaap:EquipmentMember 2015-12-31 0000931059 us-gaap:AssetsHeldUnderCapitalLeasesMember 2016-03-31 0000931059 us-gaap:AssetsHeldUnderCapitalLeasesMember 2015-12-31 0000931059 us-gaap:LeaseholdImprovementsMember 2016-03-31 0000931059 us-gaap:LeaseholdImprovementsMember 2015-12-31 0000931059 us-gaap:VehiclesMember 2016-03-31 0000931059 us-gaap:VehiclesMember 2015-12-31 0000931059 us-gaap:ComputerEquipmentMember 2016-03-31 0000931059 us-gaap:ComputerEquipmentMember 2015-12-31 0000931059 us-gaap:SoftwareDevelopmentMember 2016-03-31 0000931059 us-gaap:SoftwareDevelopmentMember 2015-12-31 0000931059 us-gaap:FurnitureAndFixturesMember 2016-03-31 0000931059 us-gaap:FurnitureAndFixturesMember 2015-12-31 0000931059 RNVA:AlcimedeMember 2016-01-01 2016-03-31 0000931059 2016-01-01 2016-03-31 0000931059 2016-03-31 0000931059 2015-01-01 2015-03-31 0000931059 us-gaap:SeriesCPreferredStockMember 2016-03-31 0000931059 us-gaap:SeriesCPreferredStockMember 2015-12-31 0000931059 RNVA:ClinicalLaboratoryOperationsMember 2016-03-31 0000931059 RNVA:ClinicalLaboratoryOperationsMember 2015-12-31 0000931059 RNVA:NotePayable1Member 2015-12-31 0000931059 RNVA:NotePayable2Member 2016-03-31 0000931059 RNVA:NotePayable3Member 2016-03-31 0000931059 RNVA:NotePayable4Member 2016-03-31 0000931059 RNVA:NotePayable5Member 2015-12-31 0000931059 RNVA:NotesPayableRelatedPartiesMember 2016-03-31 0000931059 RNVA:NotesPayableRelatedPartiesMember 2015-12-31 0000931059 RNVA:NotesPayableRelatedPartiesMember RNVA:NotePayableRelated1Member 2016-03-31 0000931059 RNVA:NotesPayableRelatedPartiesMember RNVA:NotePayableRelated1Member 2015-12-31 0000931059 RNVA:NotesPayableRelatedPartiesMember RNVA:NotePayableRelated2Member 2016-03-31 0000931059 RNVA:NotesPayableRelatedPartiesMember RNVA:NotePayableRelated3Member 2015-12-31 0000931059 RNVA:NotePayable2Member 2016-01-01 2016-03-31 0000931059 RNVA:NotePayable3Member 2016-01-01 2016-03-31 0000931059 RNVA:NotePayable4Member 2016-01-01 2016-03-31 0000931059 RNVA:NotesPayableRelatedPartiesMember RNVA:NotePayableRelated1Member 2016-01-01 2016-03-31 0000931059 RNVA:NotesPayableRelatedPartiesMember RNVA:NotePayableRelated2Member 2016-01-01 2016-03-31 0000931059 RNVA:NotesPayableRelatedPartiesMember RNVA:NotePayableRelated3Member 2016-01-01 2016-03-31 0000931059 RNVA:AlcimedeMember 2015-01-01 2015-03-31 0000931059 us-gaap:SeriesCPreferredStockMember 2015-01-01 2015-03-31 0000931059 us-gaap:SeriesCPreferredStockMember 2016-01-01 2016-03-31 0000931059 us-gaap:SeriesDPreferredStockMember 2015-01-01 2015-03-31 0000931059 us-gaap:SeriesDPreferredStockMember 2016-01-01 2016-03-31 0000931059 us-gaap:SeriesEPreferredStockMember 2015-01-01 2015-03-31 0000931059 us-gaap:SeriesEPreferredStockMember 2016-01-01 2016-03-31 0000931059 us-gaap:WarrantMember 2016-01-01 2016-03-31 0000931059 us-gaap:WarrantMember 2015-01-01 2015-03-31 0000931059 us-gaap:StockOptionMember 2016-01-01 2016-03-31 0000931059 us-gaap:StockOptionMember 2015-01-01 2015-03-31 0000931059 us-gaap:ConvertibleDebtMember 2016-01-01 2016-03-31 0000931059 us-gaap:ConvertibleDebtMember 2015-01-01 2015-03-31 0000931059 us-gaap:ConvertiblePreferredStockMember 2016-01-01 2016-03-31 0000931059 us-gaap:ConvertiblePreferredStockMember 2015-01-01 2015-03-31 0000931059 RNVA:ClinicalLaboratoryOperationsMember 2015-01-01 2015-03-31 0000931059 RNVA:DecisionSupportMember 2016-01-01 2016-03-31 0000931059 RNVA:DecisionSupportMember 2015-01-01 2015-03-31 0000931059 RNVA:DecisionSupportMember 2016-03-31 0000931059 RNVA:DecisionSupportMember 2015-12-31 0000931059 us-gaap:CorporateMember 2016-01-01 2016-03-31 0000931059 us-gaap:CorporateMember 2015-01-01 2015-03-31 0000931059 us-gaap:CorporateMember 2016-03-31 0000931059 us-gaap:CorporateMember 2015-12-31 0000931059 us-gaap:IntersegmentEliminationMember 2015-01-01 2015-03-31 0000931059 us-gaap:IntersegmentEliminationMember 2015-12-31 0000931059 us-gaap:IntersegmentEliminationMember 2016-03-31 0000931059 RNVA:SupportiveSoftwareSolutionsMember 2015-01-01 2015-03-31 0000931059 RNVA:SupportiveSoftwareSolutionsMember 2016-03-31 0000931059 2014-12-31 0000931059 2015-03-31 0000931059 RNVA:SupportiveSoftwareSolutionsMember 2016-03-31 0000931059 RNVA:SupportiveSoftwareSolutionsMember 2015-12-31 0000931059 RNVA:NotesPayableThirdPartiesMember 2016-03-31 0000931059 RNVA:NotesPayableThirdPartiesMember 2015-12-31 0000931059 RNVA:NotePayable2Member 2015-12-31 0000931059 RNVA:NotePayable3Member 2015-12-31 0000931059 RNVA:NotePayable5Member 2016-03-31 0000931059 RNVA:NotesPayableRelatedPartiesMember RNVA:NotePayableRelated2Member 2015-12-31 0000931059 RNVA:NotePayable5Member 2016-01-01 2016-03-31 0000931059 RNVA:NotePayable1Member 2015-01-01 2015-12-31 0000931059 RNVA:DDFundingMember 2016-01-01 2016-03-31 0000931059 RNVA:DDFundingMember 2016-01-01 2016-04-30 0000931059 RNVA:ConsultantMember 2016-01-01 2016-03-31 0000931059 RNVA:ClinicalLaboratoryOperationsMember 2016-03-31 0000931059 RNVA:ClinicalLaboratoryOperationsMember 2015-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

5000

45000

100000

5000000

10350

.01

.0001

.01

0.01

.01

0.01

5000

45000

8818

9000

5000

45000

8818

9000

.01

50000000

500000000

14782557

27971873

2896473

22469270

3714571

4307053

9046263

12711284

-6327245

-7095520

2677943

13357738

15152583

450

-2650540

-1313313

33660

-6764196

2214561

5065421

-881566

-1952437

-1521117

28246

-1357989

12359931

922551

991903

577316

547555

5663333

5663332

1776957

1760125

196534

753225

661234

1837174

1878848

561688

560400

12288778

5111636

5838906

5663332

5663333

2093920

2443384

3569412

3219949

1775

305188

1588495

2236112

1588495

2236112

305188

454800

453025

296348

384108

16885

2117

19002

213142

187885

25257

8833230

4900806

2406246

650505

0.00

.16

.0106

1.06

.10

.06

.20

2017-09-11

2017-07-12

2016-12-31

2016-02-02

2016-01-07

2017-03-30

2015-12-31

Rennova Health, Inc. 0000931059 10-Q 2016-03-31 false --12-31 No No Yes Smaller Reporting Company Q1 2016

581101

164428

-33661

727270

580793

447325

14527

875

1358

-28246

160356

-4244011

1007009

523050

105901690

96556901

96227506

105332339

329395

569351

175076

176361

727270

580793

130849

2263237

2270000

2263237

2270000

130849

186117

5133888

4174742

5133888

3674742

3033888

500000

1600000

500000

98225

2825661

170806

8167273

3172929

2733092

170806

5000000

100000

3000000

170806

8341612

3441612

3000000

170806

5000000

3500000

5100000

3000000

500000

1600000

500000

400000

3000000

250000

3000000

1600000

5000000

96750

85905

1432542

845330

217412

32611

3745660

350962

3394698

349464

215045

46912

-4244011

530871

354901

409638

73643

33623

28935555

9923474

6898560

1822675

9923474

8791343

11422977

.35

.34

.021

.047

-.001

.106

.37

0.00

.493

97577130 89328698

8149484

7051842

1193077

1317948

2415013

2516028

20590804

15786624

7148295

6449872

232774

4360035

3436654

269031

5269031

1323708

16372117

18804609

2903898

2898242

2394171

2070990

7495486

4123929

29165672

27897770

143951

147825

26688837

26694274

-28027177

-32271187

-1193799

-5428500

27971873

22469270

14651837

14782557

14651837

14782557

1465137

230026

1878813

13648782

13499803

183650

148979

564200

4031274

5954046

5639933

873440

1182221

522768

8643009

11434221

100010

3433588

1013413

505101

2520185

-230052

-4244011

1984509

-4244011

483959

-.29

.04

-0.29

0.04

14816586

11937530

14816586

12809335

3433588

9310 300000

56463

-789376

-246575

100000

275028

-1096357

12843394

126863

16935

-39222

-923381

-299697

-684981

417102

-101015

457769

48900

-6990241

-3792233

19002

213142

-19002

-213142

523050

3000000

5000000

3030000

4600000

60000

323181

197316

3076819

2249634

-3932424

-1755741

520000

160835

470831

0 259875 0 -138871 0 -121004

Accounts receivable at March 31, 2016 and December 31, 2015 consisted of the following:   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 56%; text-align: left">Accounts receivable - clinical laboratory operations</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">96,227,506</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">105,332,339</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Accounts receivable - supportive software solutions</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">329,395</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">569,351</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total accounts receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">96,556,901</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">105,901,690</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Less:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: 20pt">Allowance for discounts</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(89,328,698</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(97,577,130</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt; text-indent: 20pt">Allowance for bad debts</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(176,361</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(175,076</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt">Accounts receivable, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,051,842</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,149,484</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

Property and equipment at March 31, 2016 and December 31, 2015 consisted of the following:   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 56%; text-align: left">Medical equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">922,551</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">991,903</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">577,316</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">547,555</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Equipment under capital leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,663,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,663,332</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Furniture</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">561,688</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">560,400</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Leasehold improvements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,776,957</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,760,125</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Vehicles</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">196,534</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">196,534</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Computer equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">753,225</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">661,234</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Software</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,837,174</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,878,848</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,288,778</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,259,931</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Less accumulated depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(5,838,906</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(5,111,636</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">6,449,872</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">7,148,295</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table>   Depreciation of property and equipment was $727,270 and $580,793 for the three months ended March 31, 2016 and 2015, respectively.   Management periodically reviews the valuation of long-lived assets for potential impairments. Management has not recognized an impairment of these assets to date.

The Company and its subsidiaries are party to a number of loans with affiliates and unrelated parties. At March 31, 2016 and December 31, 2015, notes payable consisted of the following:   Notes Payable Third Parties   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31, 2016</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Face Value</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Unamortized</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Fair Value of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Net Value</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">of Note</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Discount</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Derivatives</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">of Note</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 44%; text-align: left">Loan payable under prepaid forward purchase contract in the amount of $5,000,000, at 20% interest, with no payments of interest or principal through March 30, 2017. All outstanding amounts are due March 30, 2017.</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">5,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">5,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Loan payable to TCA Global Master Fund, LP in the amount of $3,000,000, at 16% interest, with interest only payments monthly through September 11, 2016. Principal and interest payments are due monthly from October 11, 2016 through September 11, 2017.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(305,188</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">130,849</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,825,661</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Loan payable to CommerceNet in the amount of $250,000 at 1.06% interest, increasing to 6% after two years. Principal and interest payments are made annually from July 12, 2015 through July 12, 2017.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">170,806</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">170,806</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Loan payable to Jay Tenebaum in the amount of $250,000 at 1.06% interest, increasing to 6% after two years. Principal and interest payments are made annually from July 12, 2015 through July 12, 2017.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">170,806</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">170,806</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,341,612</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(305,188</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">130,849</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">8,167,273</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Less current portion</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(5,269,031</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Notes payable, net of current portion</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">2,898,242</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2015</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Face Value</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Unamortized</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Fair Value of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Net Value</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">of Note</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Discount</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Derivatives</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">of Note</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 44%; text-align: left">Loan payable to former shareholder of Epinex Diagnostics Laboratories, Inc. in the amount of $400,000, at 0% interest, with principal payments of $100,000 due in periodic installments from November 26, 2014 through February 26, 2016. Amount recorded is net of imputed discount of $1,775 at December 31, 2015.</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">100,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(1,775</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">98,225</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Loan payable to TCA Global Master Fund, LP in the amount of $3,000,000, at 16% interest, with interest only payments monthly through September 11, 2016. Principal and interest payments are due monthly from October 11, 2016 through September 11, 2017.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(453,025</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">186,117</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,733,092</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Loan payable to CommerceNet in the amount of $250,000 at 1.06% interest, increasing to 6% after two years. Principal and interest payments are made annually from July 12, 2015 through July 12, 2017.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">170,806</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">170,806</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Loan payable to Jay Tenebaum in the amount of $250,000 at 1.06% interest, increasing to 6% after two years. Principal and interest payments are made annually from July 12, 2015 through July 12, 2017.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">170,806</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">170,806</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,441,612</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(454,800</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">186,117</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">3,172,929</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Less current portion</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(269,031</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Notes payable, net of current portion</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">2,903,898</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table>   Notes Payable Related Parties   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31, 2016</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Face Value</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Unamortized</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Fair Value of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Net Value</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">of Note</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Discount</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Derivatives</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">of Note</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 44%; text-align: left">Convertible debenture dated December 31, 2014 in the amount of $3,000,000 which bears interest at 10% and is due December 31, 2016. The note provides the lender, D&D Funding II, LLC, the option to convert the note into the Company's common stock at a 25% discount to the average trading price (as defined in the note agreement) for the ten consecutive trading days prior to the conversion date.</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">3,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(1,588,495</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">2,263,237</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">3,674,742</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Loan payable to Alcimede, LLC in the amount of $3,000,000, at 6% interest, with one payment of $3,000,000, plus interest, due on February 2, 2017. (On June 29, 2015, Alcimede exercised options to purchase 1,000,000 shares for $2,500,000, which reduced the loan.)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">500,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt">Current portion of notes payable, related party</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,500,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,588,495</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,263,237</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,174,742</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2015</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Face Value</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Unamortized</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Fair Value of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Net Value</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">of Note</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Discount</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Derivatives</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">of Note</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 44%; text-align: left">Convertible debenture dated December 31, 2014 in the amount of $3,000,000 which bears interest at 10% and is due December 31, 2016. The note provides the lender, D&D Funding II, LLC, the option to convert the note into the Company's common stock at a 25% discount to the average trading price (as defined in the note agreement) for the ten consecutive trading days prior to the conversion date.</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">3,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(2,236,112</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">2,270,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">3,033,888</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Loan payable to Alcimede, LLC in the amount of $3,000,000, at 6% interest, with one payment of $3,000,000, plus interest, due on February 2, 2016. (On June 29, 2015, Alcimede exercised options to purchase 1,000,000 shares for $2,500,000, which reduced the loan.)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">500,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Loan payable to Christopher Diamantis in the amount of $1,600,000. One payment of $1,600,000 due January 7, 2016 plus $100,000 of interest.</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,600,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,600,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt">Current portion of notes payable, related party</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,100,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,236,112</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,270,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,133,888</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   Convertible Debenture Dated December 31, 2014   On December 31, 2014, the Company borrowed $3,000,000 from D&D Funding II, LLC (D&D), Christopher Diamantis, a director of the Company, is the manager and 50% owner of D&D. In January 2016, the Company temporarily repaid $3,000,000 of the amounts due under the D&D note. In addition to the principal amount, the Company paid $300,000 in cash for interest for 2015. In March 2016, the Company re-borrowed 100% of the principal amount repaid in January 2016. This note is convertible into the Companys Common Stock at a 25% discount to the trailing ten day average closing price at any time prior to the repayment. In the event of conversion, the holder of the note is also entitled to receive a number of warrants to purchase the Companys Common Stock equal to the number of shares issued upon conversion with exercise prices equal to the trailing ten day average closing price of our Common Stock. These two features are derivative instruments that are re-valued quarterly and are reflected in the table above.   Prepaid Forward Purchase Contract   On March 31, 2016, the Company entered into an agreement to pledge certain of its accounts receivable as collateral against a prepaid forward purchase contract. The receivables had an estimated collectable value of $8,700,000 and have been adjusted down to approximately $4,300,000 in our books and records. The consideration received was $5,000,000. In exchange for the consideration received, the counterparty received the right to: (i) a 20% per annum investment return from the Company on the consideration, with a minimum repayment term of six months and minimum return of $500,000, (ii) all payments recovered from the accounts receivable up to $5,250,000, if paid in full within six months, or $5,500,000, if not paid in full within six months, and (iii) 20% of all payments of the accounts receivable in excess of amounts received in (i) and (ii). On March 31, 2017, to the extent that the counterparty has not been paid $6,000,000, the Company is required to pay the difference. Christopher Diamantis, a director of the Company, guaranteed the Company's payment obligation of up to $6,000,000. For providing the guarantee, and to the extent that the counterparty receives amounts payable under clause (ii) above exceeding $5,000,000, Mr. Diamantis will be paid a fee by the counterparty equal to the amount by which the amount received under clause (ii) above exceeds $5,000,000 ($250,000 or $500,000, depending on the timing of payment).

The Company leases various assets under capital leases expiring through 2020 as follows:   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 56%; text-align: left">Medical equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">5,663,333</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">5,663,332</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Less accumulated depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,443,384</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(2,093,920</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; padding-bottom: 2.5pt">Net</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">3,219,949</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">3,569,412</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table>   Depreciation expense on assets under capital leases was $349,464 and $215,045 for the three months ended March 31, 2016 and 2015, respectively.   Aggregate future minimum rentals under capital leases are as follows:   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="2" style="font-weight: bold; text-align: left">December 31,</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td colspan="2" style="text-align: left">2016</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,217,765</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td colspan="2" style="text-align: left">2017</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,432,542</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td colspan="2" style="text-align: left">2018</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">845,330</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td colspan="2" style="text-align: left">2019</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">217,412</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td colspan="2" style="text-align: left">2020</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">32,611</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; width: 1%"> </td><td style="text-align: left; width: 51%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 13%"> </td><td style="text-align: left; width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td colspan="2" style="text-align: left">Total</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,745,660</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: left"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td colspan="2" style="text-align: left">Less interest</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">350,962</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: left"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td colspan="2" style="font-weight: bold; text-align: left">Present value of minimum lease payments</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">3,394,698</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: left"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td colspan="2" style="text-align: left">Less current portion of capital lease obligations</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,323,708</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: left"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td colspan="2" style="font-weight: bold; text-align: left">Capital lease obligations, net of current portion</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">2,070,990</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table>

Preferred Stock   During the three months ended March 31, 2015, the former Medytox Series B preferred shareholders earned dividends totaling $523,050. At March 31, 2016 and December 31, 2015, accrued dividends of $1,684,148 and $2,099,148, respectively, were included in accrued expenses. All outstanding Medytox Series B preferred shares were cancelled in connection with the Merger in exchange for shares of Rennova Series B Convertible Preferred Stock, which only receives dividends when dividends are declared on our common stock.   During the three months ended March 31, 2016, Series C preferred shareholders converted a total of 182 shares of Series C preferred stock into 117,420 shares of Common Stock.   Common Stock   During the three months ended March 31, 2016, the Company issued an aggregate of 13,300 shares of the Companys common stock to a consultant for services. The Company recognized $9,310 in compensation costs associated with these issuances.   Stock Options   During the three months ended March 31, 2016 and 2015, no stock options were granted or forfeited.   Basic and Diluted Income per Share   The following table presents the reconciliation of the numerators and denominators used in the calculation of earnings per share for the three months ended March 31, 2016 and 2015. For the three months ended March 31, 2015, all share and per share amounts have been restated as a result of the Merger.   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold">Basic:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 66%; text-align: left; text-indent: 10pt">Numerator - net income (loss) available to common stockholders</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(4,244,011</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">483,959</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt; text-indent: 10pt">Denominator - weighted-average shares outstanding</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">14,816,586</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">11,937,530</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: 20.1pt">Net income (loss) per share - Basic</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(0.29</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">0.04</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold">Diluted:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: 10pt">Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; text-indent: 20pt">Net income (loss) available to common stockholders</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(4,244,011</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">483,959</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: 20pt">Interest expense on convertible debt, net of taxes</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">46,912</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(4,244,011</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">530,871</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-indent: 10pt">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: 20pt">Weighted-average shares outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,816,586</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,937,530</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; text-indent: 20pt">Weighted-average equivalent shares options and warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">354,901</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: 20pt">Weighted-average equivalent shares from convertible debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">409,638</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; text-indent: 20pt">Weighted-average equivalent shares from Series C convertible preferred stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: 20pt">Weighted-average equivalent shares from Series D convertible preferred stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">73,643</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt; text-indent: 20pt">Weighted-average equivalent shares from Series E convertible preferred stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">33,623</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">14,816,586</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">12,809,335</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: 30.1pt">Net income (loss) per share - Diluted</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(0.29</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">0.04</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table>   Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. As of March 31, 2016 and 2015, the following potential common stock equivalents were excluded from the calculation of Diluted EPS as their effect was anti-dilutive:   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 56%; text-align: left">Stock options outstanding</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">1,822,675</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">9,923,474</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,898,560</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Convertible debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,791,343</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Convertible preferred stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">11,422,977</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">28,935,555</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">9,923,474</td></tr></table>

The Company recognized no income tax expense or benefit for the three months ended March 31, 2016. The Company recognized income tax expense of $977,500 for the three months ended March 31, 2015. The Companys effective income tax rates for the three months ended March 31, 2016 and 2015 were 0.0% and 49.3%, respectively.   Changes to the effective tax rates relate primarily to the recognition of a valuation allowance on 100% of net deferred tax assets for the three months ended March 31, 2016.   The Company applies a more likely than not threshold to the recognition and nonrecognition of tax positions. A change in judgment related to prior years tax positions is recognized in the quarter of such change. The Company had no reserve for uncertain tax positions as of March 31, 2016 or December 31, 2015. The Company recognizes interest and/or penalties related to income tax matters in income tax expense and in income taxes payable.   The table below presents a reconciliation of statutory income tax rates to our effective rates:   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 56%; text-align: left">Expected federal income tax at statutory rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">35.0%</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">34.0%</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State income taxes, net of federal deduction</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2.1%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.7%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Permanent differences</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-0.1%</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10.6%</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-37.0%</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">0.0%</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">0.0%</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">49.3%</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr></table>

Completion of Merger   On November 2, 2015, the Company completed its merger (the Merger) with Medytox Solutions, Inc. (Medytox). In connection with the Merger, (i) each share of common stock of Medytox was converted into the right to receive about 0.4096 shares of common stock of CollabRx, (ii) each share of Series B Preferred Stock of Medytox was converted into the right to receive one share of a newly-authorized Series B Convertible Preferred Stock of CollabRx, and (iii) each share of Series E Convertible Preferred Stock of Medytox was converted into the right to receive one share of a newly-authorized Series E Convertible Preferred Stock of CollabRx.   Holders of CollabRx equity prior to the closing of the Merger (including all outstanding CollabRx common stock and all restricted stock units, options and warrants exercisable for shares of CollabRx common stock) held 10% of CollabRxs common stock immediately following the closing of the Merger, and holders of Medytox equity prior to the closing of the Merger (including all outstanding Medytox common stock and all outstanding options exercisable for shares of Medytox common stock, but less certain options that were cancelled upon the closing pursuant to agreements between Medytox and such optionees) held 90% of CollabRxs common stock immediately following the closing of the Merger, in each case on a fully diluted basis, provided, however, outstanding shares of the newly designated Series B Convertible Preferred Stock and Series E Convertible Preferred Stock, certain outstanding convertible promissory notes exercisable for CollabRx common stock after the closing and certain option grants expected to be made at or immediately following the closing of the Merger are excluded from such ownership percentages.   Also in connection with the Merger: (i) each of James Karis, Jeffrey M. Kraus and Carl Muscari resigned from CollabRxs Board of Directors; (ii) each of Seamus Lagan, Christopher Diamantis, Benjamin Frank, Michael L. Goldberg and Robert Lee was appointed to serve on CollabRxs Board of Directors; and (iii) Thomas R. Mika was appointed Chairman of the Board, Seamus Lagan was appointed Chief Executive Officer and President, Jason Adams was appointed Chief Financial Officer, and Sebastian Sainsbury was appointed Secretary.   Prior to the closing of the Merger, the Company amended its certificate of incorporation to effect a 1-for-10 reverse split and to change its name to Rennova Health, Inc. On November 3, 2015, the common stock of Rennova commenced trading on the Nasdaq Capital Market under the symbol RNVA. Immediately after the consummation of the Merger, Rennova had 13,750,010 shares of common stock, 5,000 shares of Series B Convertible Preferred Stock and 45,000 shares of Series E Convertible Preferred Stock issued and outstanding.   The transaction was accounted for as a reverse acquisition. As such, the prior period equity amounts have been retroactively restated to reflect the equity instruments of the legal acquirer. The consideration given for CollabRx totals $12,289,297, consisting of the fair value of common stock and warrants exchanged in the merger transaction.   The Company acquired the remaining 49.5% of Biohealth in the three months ended March 31, 2015. The Company accounted for the assets, liabilities and ownership interests in accordance with the provisions of FASB ASC 805 Business Combinations. As such, the recorded assets and liabilities acquired have been recorded at fair value and any difference in the net asset values and the consideration given was recorded as goodwill.

Selected financial information for the Companys operating segments is as follows:   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Net revenues - External</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 56%; text-align: left; padding-left: 10pt">Clinical Laboratory Operations</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,465,137</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">13,499,803</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-left: 10pt">Supportive Software Solutions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">230,026</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">148,979</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Decision Support and Informatics Operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">183,650</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt">Corporate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; padding-left: 10pt">Eliminations</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,878,813</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,648,782</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net revenues - Inter Segment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-left: 10pt">Clinical Laboratory Operations</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Supportive Software Solutions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">296,348</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">384,108</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-left: 10pt">Decision Support and Informatics Operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Corporate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt; padding-left: 10pt">Eliminations</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">296,348</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">384,108</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Income (loss) from operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Clinical Laboratory Operations</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(2,650,540</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5,065,421</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-left: 10pt">Supportive Software Solutions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,313,313</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,357,989</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Decision Support and Informatics Operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(881,566</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt">Corporate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,952,437</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,521,117</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; padding-left: 10pt">Eliminations</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">33,660</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">28,246</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(6,764,196</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,214,561</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Depreciation and amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-left: 10pt">Clinical Laboratory Operations</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">581,101</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">447,325</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Supportive Software Solutions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">164,428</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">160,356</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-left: 10pt">Decision Support and Informatics Operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,527</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Corporate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">875</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,358</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt; padding-left: 10pt">Eliminations</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(33,661</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(28,246</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">727,270</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">580,793</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Capital expenditures</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Clinical Laboratory Operations</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">16,885</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">187,885</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-left: 10pt">Supportive Software Solutions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,117</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,257</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Decision Support and Informatics Operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt">Corporate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; padding-left: 10pt">Eliminations</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">19,002</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">213,142</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Total assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 56%; text-align: left; padding-left: 10pt">Clinical Laboratory Operations</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">13,357,738</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">15,152,583</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-left: 10pt">Supportive Software Solutions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,677,943</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,896,473</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Decision Support and Informatics Operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,714,571</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,307,053</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt">Corporate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,046,263</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,711,284</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; padding-left: 10pt">Eliminations</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(6,327,245</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(7,095,520</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,469,270</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">27,971,873</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 56%; text-align: left">Accounts receivable - clinical laboratory operations</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">96,227,506</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">105,332,339</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Accounts receivable - supportive software solutions</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">329,395</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">569,351</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total accounts receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">96,556,901</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">105,901,690</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td>Less:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: 20pt">Allowance for discounts</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(89,328,698</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(97,577,130</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt; text-indent: 20pt">Allowance for bad debts</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(176,361</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(175,076</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt">Accounts receivable, net</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">7,051,842</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,149,484</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 56%; text-align: left">Medical equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">922,551</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">991,903</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">577,316</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">547,555</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Equipment under capital leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,663,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,663,332</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Furniture</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">561,688</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">560,400</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Leasehold improvements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,776,957</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,760,125</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Vehicles</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">196,534</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">196,534</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Computer equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">753,225</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">661,234</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Software</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,837,174</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,878,848</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,288,778</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,259,931</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Less accumulated depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(5,838,906</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(5,111,636</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Property and equipment, net</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">6,449,872</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">7,148,295</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31, 2016</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Face Value</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Unamortized</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Fair Value of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Net Value</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">of Note</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Discount</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Derivatives</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">of Note</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 44%; text-align: left">Loan payable under prepaid forward purchase contract in the amount of $5,000,000, at 20% interest, with no payments of interest or principal through March 30, 2017. All outstanding amounts are due March 30, 2017.</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">5,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">5,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Loan payable to TCA Global Master Fund, LP in the amount of $3,000,000, at 16% interest, with interest only payments monthly through September 11, 2016. Principal and interest payments are due monthly from October 11, 2016 through September 11, 2017.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(305,188</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">130,849</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,825,661</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Loan payable to CommerceNet in the amount of $250,000 at 1.06% interest, increasing to 6% after two years. Principal and interest payments are made annually from July 12, 2015 through July 12, 2017.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">170,806</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">170,806</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Loan payable to Jay Tenebaum in the amount of $250,000 at 1.06% interest, increasing to 6% after two years. Principal and interest payments are made annually from July 12, 2015 through July 12, 2017.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">170,806</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">170,806</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">8,341,612</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(305,188</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">130,849</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">8,167,273</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Less current portion</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(5,269,031</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Notes payable, net of current portion</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">2,898,242</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2015</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Face Value</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Unamortized</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Fair Value of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Net Value</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">of Note</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Discount</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Derivatives</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">of Note</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 44%; text-align: left">Loan payable to former shareholder of Epinex Diagnostics Laboratories, Inc. in the amount of $400,000, at 0% interest, with principal payments of $100,000 due in periodic installments from November 26, 2014 through February 26, 2016. Amount recorded is net of imputed discount of $1,775 at December 31, 2015.</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">100,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(1,775</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"></td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">98,225</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Loan payable to TCA Global Master Fund, LP in the amount of $3,000,000, at 16% interest, with interest only payments monthly through September 11, 2016. Principal and interest payments are due monthly from October 11, 2016 through September 11, 2017.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(453,025</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">186,117</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,733,092</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Loan payable to CommerceNet in the amount of $250,000 at 1.06% interest, increasing to 6% after two years. Principal and interest payments are made annually from July 12, 2015 through July 12, 2017.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">170,806</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">170,806</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Loan payable to Jay Tenebaum in the amount of $250,000 at 1.06% interest, increasing to 6% after two years. Principal and interest payments are made annually from July 12, 2015 through July 12, 2017.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">170,806</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">170,806</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,441,612</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(454,800</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">186,117</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">3,172,929</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt">Less current portion</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(269,031</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Notes payable, net of current portion</td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">2,903,898</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31, 2016</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Face Value</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Unamortized</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Fair Value of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Net Value</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">of Note</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Discount</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Derivatives</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">of Note</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 44%; text-align: left">Convertible debenture dated December 31, 2014 in the amount of $3,000,000 which bears interest at 10% and is due December 31, 2016. The note provides the lender, D&D Funding II, LLC, the option to convert the note into the Company's common stock at a 25% discount to the average trading price (as defined in the note agreement) for the ten consecutive trading days prior to the conversion date.</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">3,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(1,588,495</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">2,263,237</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">3,674,742</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Loan payable to Alcimede, LLC in the amount of $3,000,000, at 6% interest, with one payment of $3,000,000, plus interest, due on February 2, 2017. (On June 29, 2015, Alcimede exercised options to purchase 1,000,000 shares for $2,500,000, which reduced the loan.)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">500,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt">Current portion of notes payable, related party</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,500,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,588,495</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,263,237</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,174,742</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31, 2015</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Face Value</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Unamortized</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Fair Value of</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Net Value</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">of Note</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Discount</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">Derivatives</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">of Note</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="width: 44%; text-align: left">Convertible debenture dated December 31, 2014 in the amount of $3,000,000 which bears interest at 10% and is due December 31, 2016. The note provides the lender, D&D Funding II, LLC, the option to convert the note into the Company's common stock at a 25% discount to the average trading price (as defined in the note agreement) for the ten consecutive trading days prior to the conversion date.</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">3,000,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">(2,236,112</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">2,270,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">3,033,888</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Loan payable to Alcimede, LLC in the amount of $3,000,000, at 6% interest, with one payment of $3,000,000, plus interest, due on February 2, 2016. (On June 29, 2015, Alcimede exercised options to purchase 1,000,000 shares for $2,500,000, which reduced the loan.)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">500,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Loan payable to Christopher Diamantis in the amount of $1,600,000. One payment of $1,600,000 due January 7, 2016 plus $100,000 of interest.</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,600,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,600,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 2.5pt">Current portion of notes payable, related party</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,100,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(2,236,112</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,270,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">5,133,888</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="2" style="font-weight: bold; text-align: left">December 31,</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td colspan="2" style="text-align: left">2016</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,217,765</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td colspan="2" style="text-align: left">2017</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,432,542</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td colspan="2" style="text-align: left">2018</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">845,330</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td colspan="2" style="text-align: left">2019</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">217,412</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td colspan="2" style="text-align: left">2020</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">32,611</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; width: 1%"> </td><td style="text-align: left; width: 51%"> </td><td style="text-align: left; width: 1%"> </td><td style="width: 2%"> </td> <td style="text-align: left; width: 1%"> </td><td style="text-align: right; width: 13%"> </td><td style="text-align: left; width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td colspan="2" style="text-align: left">Total</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,745,660</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: left"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td colspan="2" style="text-align: left">Less interest</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">350,962</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: left"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td colspan="2" style="font-weight: bold; text-align: left">Present value of minimum lease payments</td><td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td style="font-weight: bold; text-align: right">3,394,698</td><td style="font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: left"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td colspan="2" style="text-align: left">Less current portion of capital lease obligations</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,323,708</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"> </td><td style="text-align: left"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td colspan="2" style="font-weight: bold; text-align: left">Capital lease obligations, net of current portion</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">2,070,990</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold">Basic:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 66%; text-align: left; text-indent: 10pt">Numerator - net income (loss) available to common stockholders</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(4,244,011</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 13%; text-align: right">483,959</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt; text-indent: 10pt">Denominator - weighted-average shares outstanding</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">14,816,586</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">11,937,530</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: 20.1pt">Net income (loss) per share - Basic</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(0.29</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">0.04</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="font-weight: bold">Diluted:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: 10pt">Numerator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; text-indent: 20pt">Net income (loss) available to common stockholders</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(4,244,011</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">483,959</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; text-indent: 20pt">Interest expense on convertible debt, net of taxes</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">46,912</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(4,244,011</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">530,871</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-indent: 10pt">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: 20pt">Weighted-average shares outstanding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,816,586</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">11,937,530</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; text-indent: 20pt">Weighted-average equivalent shares options and warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">354,901</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: 20pt">Weighted-average equivalent shares from convertible debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">409,638</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; text-indent: 20pt">Weighted-average equivalent shares from Series C convertible preferred stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: 20pt">Weighted-average equivalent shares from Series D convertible preferred stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">73,643</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-bottom: 1pt; text-indent: 20pt">Weighted-average equivalent shares from Series E convertible preferred stock</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">33,623</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">14,816,586</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">12,809,335</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: 30.1pt">Net income (loss) per share - Diluted</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(0.29</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">0.04</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three Months Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Net revenues - External</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 56%; text-align: left; padding-left: 10pt">Clinical Laboratory Operations</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">1,465,137</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">13,499,803</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-left: 10pt">Supportive Software Solutions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">230,026</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">148,979</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Decision Support and Informatics Operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">183,650</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt">Corporate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; padding-left: 10pt">Eliminations</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,878,813</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">13,648,782</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Net revenues - Inter Segment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-left: 10pt">Clinical Laboratory Operations</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Supportive Software Solutions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">296,348</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">384,108</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-left: 10pt">Decision Support and Informatics Operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Corporate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt; padding-left: 10pt">Eliminations</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">296,348</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">384,108</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Income (loss) from operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Clinical Laboratory Operations</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(2,650,540</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">5,065,421</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-left: 10pt">Supportive Software Solutions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,313,313</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,357,989</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Decision Support and Informatics Operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(881,566</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt">Corporate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,952,437</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,521,117</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; padding-left: 10pt">Eliminations</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">33,660</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">28,246</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(6,764,196</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,214,561</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Depreciation and amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-left: 10pt">Clinical Laboratory Operations</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">581,101</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">447,325</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Supportive Software Solutions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">164,428</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">160,356</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-left: 10pt">Decision Support and Informatics Operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,527</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Corporate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">875</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,358</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 1pt; padding-left: 10pt">Eliminations</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(33,661</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(28,246</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">727,270</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">580,793</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Capital expenditures</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Clinical Laboratory Operations</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">16,885</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">187,885</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-left: 10pt">Supportive Software Solutions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,117</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,257</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Decision Support and Informatics Operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt">Corporate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; padding-left: 10pt">Eliminations</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">19,002</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">213,142</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>   <table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">March 31,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2016</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left">Total assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 56%; text-align: left; padding-left: 10pt">Clinical Laboratory Operations</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">13,357,738</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">15,152,583</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="text-align: left; padding-left: 10pt">Supportive Software Solutions</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,677,943</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,896,473</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 10pt">Decision Support and Informatics Operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,714,571</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,307,053</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-left: 10pt">Corporate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,046,263</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,711,284</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; padding-left: 10pt">Eliminations</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(6,327,245</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(7,095,520</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(238,238,238)"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">22,469,270</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">27,971,873</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

5285455

4600474

1285

977500

1285

6473733

5000000

1775

3000000

2250000

300000

1217765

2099148

1684148

182

117420

13300

9310

93699

Rennova Health, Inc. (Rennova), together with its subsidiaries (the Company, we, us or our), is a vertically integrated provider of healthcare related products and services. Our principal lines of business are clinical laboratory operations, supportive software solutions, which includes EHR (Electronic Health Records), Medical Billing Services, and LIS (Lab Information Services), and decision support and informatics operations. We present our financial results based upon our three business segments listed above.   Merger between the Company and Medytox Solutions, Inc.   On November 2, 2015, pursuant to the terms of the Agreement and Plan of Merger, dated as of April 15, 2015, by and among the Company, CollabRx Merger Sub, Inc. (Merger Sub), a direct wholly-owned subsidiary of the Company formed for the purpose of the merger, and Medytox Solutions, Inc. (Medytox), Merger Sub merged with and into Medytox, with Medytox as the surviving company and a direct, wholly-owned subsidiary of the Company (the Merger). Prior to closing, the Company amended its certificate of incorporation to effect a 1-for-10 reverse stock split and to change its name to Rennova Health, Inc. In connection with the Merger, (i) each share of common stock of Medytox was converted into the right to receive approximately 0.4096 shares of common stock of the Company, (ii) each share of Series B Preferred Stock of Medytox was converted into the right to receive one share of a newly-authorized Series B Convertible Preferred Stock of the Company, and (iii) each share of Series E Convertible Preferred Stock of Medytox was converted into the right to receive one share of a newly-authorized Series E Convertible Preferred Stock of the Company. This transaction has been accounted for as a reverse merger in accordance with Generally Accepted Accounting Principles in the United States ("US GAAP") and, as such, the financial statements presented prior to November 2, 2015 are those of Medytox and the financial statements presented after November 2, 2015 reflect the operations, of the combined company. All common share amounts prior to November 2, 2015 have been retroactively restated to reflect the conversion ratio.   Holders of Company equity prior to the closing of the Merger (including all outstanding Company common stock and all restricted stock units, options and warrants exercisable for shares of Company common stock) held 10% of the Company's common stock immediately following the closing of the Merger, and holders of Medytox equity prior to the closing of the Merger (including all outstanding Medytox common stock and all outstanding options exercisable for shares of Medytox common stock, but less certain options that were cancelled upon the closing pursuant to agreements between Medytox and such optionees) held 90% of the Company's common stock immediately following the closing of the Merger, in each case on a fully diluted basis, provided, however, outstanding shares of the newly designated Series B Convertible Preferred Stock and Series E Convertible Preferred Stock, certain outstanding convertible promissory notes exercisable for Company common stock after the closing and certain option grants expected to be made following the closing of the Merger are excluded from such ownership percentages.   On November 3, 2015, the common stock of Rennova Health, Inc. commenced trading on the Nasdaq Capital Market under the symbol RNVA. Prior to that date, our common stock was listed on the NASDAQ Capital Market under the symbol CLRX. Immediately after the consummation of the Merger, the Company had 13,750,010 shares of common stock, 5,000 shares of Series B Convertible Preferred Stock and 45,000 shares of Series E Convertible Preferred Stock issued and outstanding.   Potential De-Listing of the Companys Stock   On March 16, 2016, the Company was notified by Nasdaq that the bid price of the Company's common stock closed below the minimum $1.00 share requirement for continued inclusion under Nasdaq Rule 5550(a)(2) (the Bid Price Rule). In accordance with Nasdaq Rule 5810(c)(3)(A), the Company has 180 calendar days, or until September 12, 2016, to regain compliance. If at any time before September 12, 2016, the bid price of the Company's common stock closes at $1.00 per share or more for a minimum of 10 consecutive business days, the Company will regain compliance with the Bid Price Rule. If the Company does not regain compliance by September 12, 2016, an additional 180 days may be granted to regain compliance, so long as the Company meets The Nasdaq Capital Market initial listing criteria (except for the bid price requirement).   On April 26, 2016, the Company was notified by Nasdaq that the stockholders equity balance reported on its Form 10-K for the year ended December 31, 2015 fell below the $2,500,000 minimum requirement for continued listing under the Nasdaq Capital Markets Listing Rule 5550(b)(1) (the Equity Rule). As of December 31, 2015, the Companys stockholders equity balance was $(1,193,799). In accordance with the Equity Rule, the Company has until June 10, 2016 to prepare and submit a plan to Nasdaq outlining how it intends to regain compliance. If the plan is accepted, the Company can be granted up to 180 calendar days from April 26, 2016 to evidence compliance. There can be no guarantee that the Company will be able to regain compliance with the continued listing requirement of the Equity Rule or that its plan will be accepted by Nasdaq.   Basis of Presentation   The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with US GAAP for interim financial statement presentation and in accordance with Form 10-Q. Accordingly, they do not include all of the information and footnotes required in annual financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements contain all adjustments (consisting only of normal recurring accruals) necessary to present fairly the financial position and results of operations and cash flows for the interim periods reported in this Form 10-Q. The results of operations presented are not necessarily indicative of the results to be expected for any other interim period or for the entire year.   These unaudited interim condensed consolidated financial statements should be read in conjunction with the 2015 audited annual financial statements included in the Annual Report on Form 10-K/A, filed with the U.S. Securities and Exchange Commission (SEC) on May 17, 2016.   The Companys consolidated financial statements are prepared using US GAAP applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business. However, the Company has recently accumulated significant losses and has negative cash flows from operations, which raise substantial doubt about its ability to continue as a going concern. Management's plans with respect to alleviating the adverse financial conditions that caused management to express substantial doubt about the Companys ability to continue as a going concern are as follows:   The Company is currently executing on a plan of action to increase the volume of samples processed by its labs. In addition, the Company is executing on a plan of action to increase the number of customers for its supportive software solutions. While the results of these plans of action are encouraging, no conclusion can be drawn at this time about the ultimate efficacy of these plans of action.   In order to support the Companys continued operations, the Company received proceeds of $5,000,000 from pledging certain of its accounts receivable as collateral to a prepaid forward purchase contract. The Company is also entitled to $2,516,028 in income tax refunds, the claim for which was filed with the IRS in early April 2016. There can be no assurance as to the timing of the receipt of the income tax refunds for which the Company has filed.   There can be no assurance that the Company will be able to achieve its business plans, raise any more required capital or secure the financing necessary to achieve its current operating plan.  The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plan described in the preceding paragraphs and eventually regain profitable operations. The accompanying consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

On April 26, 2016, the Company was notified by Nasdaq that the stockholders equity balance reported on its Form 10-K for the year ended December 31, 2015 fell below the $2,500,000 minimum requirement for continued listing under the Nasdaq Capital Markets Listing Rule 5550(b)(1) (the Equity Rule). As of December 31, 2015, the Companys stockholders equity balance was $(1,193,799). In accordance with the Equity Rule, the Company has until June 10, 2016 to prepare and submit a plan to Nasdaq outlining how it intends to regain compliance. If the plan is accepted, the Company can be granted up to 180 calendar days from April 26, 2016 to evidence compliance. There can be no guarantee that the Company will be able to regain compliance with the continued listing requirement of the Equity Rule or that its plan will be accepted by Nasdaq.   In April 2016, the Company repaid $2,250,000 of the $3,000,000 then outstanding under the D&D note from proceeds of the prepaid forward purchase contract discussed above. This note was convertible into the Companys Common Stock at a 25% discount to the trailing ten day average closing price at any time prior to the repayment. As such, the Company elected to repay a portion of the note prior to its maturity date.   The Company has evaluated subsequent events through the date the financial statements were issued and filed with SEC. The Company has determined that there are no other events that warrant disclosure or recognition in the financial statements.

EX-101.SCH 8 rnva-20160331.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - 1. Organization and Presentation link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - 2. Accounts Receivable link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - 3. Long-Lived Assets link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - 4. Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - 5. Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - 6. Capital Lease Obligations link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - 7. Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - 8. Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - 9. Business Combinations link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - 10. Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - 11. Segment Reporting link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - 12. Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - 2. Accounts Receivable (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - 3. Long-Lived Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - 4. Notes Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - 6. Capital Lease Obligations (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - 7. Stockholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - 8. Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - 11. Segment Reporting (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - 1. Organization and Presentation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - 2. Accounts Receivable (Details - Accounts receivable) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - 3. Long-Lived Assets (Details - Equipment) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - 3. Long-Lived Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - 4. Notes Payable (Details-Notes Payable) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - 4. Notes Payable (Details-Notes Payable Related Party) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - 4. Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - 5. Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - 6. Capital Lease Obligations (Details-Capital leased assets) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - 6. Capital Lease Obligations (Details-Future payments) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - 6. Capital Lease Obligations (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - 7. Stockholders Equity Earnings (Details-EPS) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - 7. Stockholders' Equity (Details - Antidilutive shares) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - 7. Stockholders' Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - 8. Income Taxes (Details-Effective income tax rate) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - 8. Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - 11. Segment Reporting (Details-Operations) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - 11. Segment Reporting (Details-Assets) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 rnva-20160331_cal.xml XBRL CALCULATION FILE EX-101.DEF 10 rnva-20160331_def.xml XBRL DEFINITION FILE EX-101.LAB 11 rnva-20160331_lab.xml XBRL LABEL FILE Series B Preferred Stock [Member] Class of Stock [Axis] Series E Preferred Stock [Member] Supportive Software Solutions [Member] Segments [Axis] Clinical Laboratory Operations [Member] Eliminations [Member] Consolidation Items [Axis] Medical equipment [Member] Property, Plant and Equipment, Type [Axis] Equipment [Member] Assets Held Under Capital Leases [Member] Leasehold Improvements [Member] Vehicles [Member] Computer Equipment [Member] Software [Member] Furniture [Member] Alcimede [Member] Related Party [Axis] Series C Preferred Stock [Member] Receivable Type [Axis] Note payable 1 [Member] Long-term Debt, Type [Axis] Note payable 2 [Member] Note payable 3 [Member] Note payable 4 [Member] Note payable 5 [Member] Notes payable - related party [Member] Related Party Transaction [Axis] Notes payable - related party 1 [Member] Notes payable - related party 2 [Member] Notes payable - related party 3 [Member] Series D Preferred Stock [Member] Warrant [Member] Antidilutive Securities [Axis] Stock Options [Member] Convertible Debt [Member] Convertible Preferred Stock [Member] Decision Support and Informatics Operations [Member] Corporate [Member] Notes Payable - Third Parties [Member] D & D Funding [Member] Consultant [Member] Counterparty Name [Axis] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Public Float Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement [Table] Statement [Line Items] ASSETS Current assets: Cash Accounts receivable, net Prepaid expenses and other current assets Income tax refunds receivable Total current assets Property and equipment, net Other assets: Deposits Total assets LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable Accrued expenses Current portion of notes payable Current portion of notes payable, related party Current portion of capital lease obligation Total current liabilities Other liabilities: Notes payable, net of current portion Capital lease obligations, net of current portion Derivative liabilities Total liabilities Commitments and contingencies Stockholders' equity: Preferred stock, 5,000,000 shares authorized: Common stock, $0.01 par value, 500,000,000 shares authorized, 14,782,557 shares issued and outstanding at March 31, 2016, 50,000,000 shares authorized, 14,651,837 shares issued and outstanding at December 31, 2015 Additional paid-in-capital (Accumulated deficit) retained earnings Total stockholders' equity Total liabilities and stockholders' equity Preferred stock shares authorized Preferred stock par value Preferred stock shares issued Preferred stock shares outstanding Common stock par value Common stock shares authorized Common stock shares issued Common stock shares outstanding Income Statement [Abstract] Revenues Net Revenues Operating expenses: Direct costs of revenue General and administrative Sales and marketing expenses Engineering Bad debt Depreciation and amortization Total operating expenses Income (Loss) from operations Other income (expense): Other income Unrealized gain (loss) on derivative instruments Gain (Loss) on legal settlement Interest expense Total other income (expense) Income (Loss) before income taxes Provision for income taxes Net income (loss) attributable to Rennova Health Preferred stock dividends Net income (loss) attributable to Rennova Health common shareholders Net income (loss) per common share: Basic Net income (loss) per common share: Diluted Weighted average number of shares outstanding during the period - Basic Weighted average number of shares outstanding during the period - Diluted Statement of Cash Flows [Abstract] Cash flows provided by (used in) operating activities: Net income (loss) Adjustments to reconcile net income (loss) to net cash provided by operations: Non-cash gain on derivative instruments Stock issued in lieu of cash compensation Stock-based compensation Bad debts Accretion of beneficial conversion feature as interest Accretion of debt discount Gain on extinguishment of debt Gain on legal settlement Changes in operating assets and liabilities: Accounts receivable Prepaid expenses and other current assets Security deposits Accounts payable Accrued expenses Income tax assets and liabilities Deferred tax liabilities Net cash used in operating activities Cash flows provided by (used in) investing activities: Purchase of property and equipment Net cash provided by investing activities Cash flows provided by (used in) financing activities: Dividends on Series B preferred stock Proceeds from issuance of notes payable, related party Proceeds from issuance of notes payable Payments on notes payable Payments on capital lease obligations Net cash provided by financing activities Net decrease in cash Cash at beginning of period Cash at end of period Supplemental disclosure of cash flow information: Cash paid for interest Cash paid for taxes Non-cash investing and financing activities: Acquisition of noncontrolling interest in Biohealth Medical Laboratory, Inc.: Deposits on acquisitions Goodwill Noncontrolling interest Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization and Presentation Receivables [Abstract] Accounts Receivable Property, Plant and Equipment [Abstract] Long-Lived Assets Debt Disclosure [Abstract] Notes Payable Related Party Transactions [Abstract] Related Party Transactions Capital Lease Obligations Equity [Abstract] Stockholders' Equity Income Tax Disclosure [Abstract] Income Taxes Business Combinations [Abstract] Business Combinations Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Segment Reporting [Abstract] Segment Reporting Subsequent Events [Abstract] Subsequent Events EX-101.PRE 12 rnva-20160331_pre.xml XBRL PRESENTATION FILE XML 13 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2016	May. 09, 2016
Document And Entity Information
Entity Registrant Name	Rennova Health, Inc.
Entity Central Index Key	0000931059
Document Type	10-Q
Document Period End Date	Mar. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		14,782,557
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2016

XML 14 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Cash	$ 4,900,806	$ 8,833,230
Accounts receivable, net	7,051,842	8,149,484
Prepaid expenses and other current assets	1,317,948	1,193,077
Income tax refunds receivable	2,516,028	2,415,013
Total current assets	15,786,624	20,590,804
Property and equipment, net	6,449,872	7,148,295
Other assets:
Deposits	232,774	232,774
Total assets	22,469,270	27,971,873
Current liabilities:
Accounts payable	3,436,654	4,360,035
Accrued expenses	4,600,474	5,285,455
Current portion of notes payable	5,269,031	269,031
Current portion of notes payable, related party	4,174,742	5,133,888
Current portion of capital lease obligation	1,323,708	1,323,708
Total current liabilities	18,804,609	16,372,117
Other liabilities:
Notes payable, net of current portion	2,898,242	2,903,898
Capital lease obligations, net of current portion	2,070,990	2,394,171
Derivative liabilities	4,123,929	7,495,486
Total liabilities	$ 27,897,770	$ 29,165,672
Commitments and contingencies
Stockholders' equity:
Common stock, $0.01 par value, 500,000,000 shares authorized, 14,782,557 shares issued and outstanding at March 31, 2016, 50,000,000 shares authorized, 14,651,837 shares issued and outstanding at December 31, 2015	$ 147,825	$ 143,951
Additional paid-in-capital	26,694,274	26,688,837
(Accumulated deficit) retained earnings	(32,271,187)	(28,027,177)
Total stockholders' equity	(5,428,500)	(1,193,799)
Total liabilities and stockholders' equity	22,469,270	27,971,873
Series B Preferred Stock [Member]
Stockholders' equity:
Preferred stock, 5,000,000 shares authorized:	50	50
Series C Preferred Stock [Member]
Stockholders' equity:
Preferred stock, 5,000,000 shares authorized:	88	90
Series E Preferred Stock [Member]
Stockholders' equity:
Preferred stock, 5,000,000 shares authorized:	$ 450	$ 450

XML 15 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2016	Dec. 31, 2015
Preferred stock shares authorized	5,000,000
Common stock par value	$ .01	$ .01
Common stock shares authorized	500,000,000	50,000,000
Common stock shares issued	14,782,557	14,651,837
Common stock shares outstanding	14,782,557	14,651,837
Series B Preferred Stock [Member]
Preferred stock shares authorized	5,000	5,000
Preferred stock par value	$ .01	$ .0001
Preferred stock shares issued	5,000	5,000
Preferred stock shares outstanding	5,000	5,000
Series C Preferred Stock [Member]
Preferred stock shares authorized	10,350	10,350
Preferred stock par value	$ .01	$ 0.01
Preferred stock shares issued	8,818	9,000
Preferred stock shares outstanding	8,818	9,000
Series E Preferred Stock [Member]
Preferred stock shares authorized	45,000	100,000
Preferred stock par value	$ .01	$ 0.01
Preferred stock shares issued	45,000	45,000
Preferred stock shares outstanding	45,000	45,000

XML 16 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Revenues
Net Revenues	$ 1,878,813	$ 13,648,782
Operating expenses:
Direct costs of revenue	564,200	4,031,274
General and administrative	5,954,046	5,639,933
Sales and marketing expenses	873,440	1,182,221
Engineering	522,768	0
Bad debt	1,285	0
Depreciation and amortization	727,270	580,793
Total operating expenses	8,643,009	11,434,221
Income (Loss) from operations	(6,764,196)	2,214,561
Other income (expense):
Other income	100,010	21
Unrealized gain (loss) on derivative instruments	3,433,588	0
Gain (Loss) on legal settlement	0	275,028
Interest expense	(1,013,413)	(505,101)
Total other income (expense)	2,520,185	(230,052)
Income (Loss) before income taxes	(4,244,011)	1,984,509
Provision for income taxes	0	977,500
Net income (loss) attributable to Rennova Health	(4,244,011)	1,007,009
Preferred stock dividends	0	523,050
Net income (loss) attributable to Rennova Health common shareholders	$ (4,244,011)	$ 483,959
Net income (loss) per common share: Basic	$ (.29)	$ .04
Net income (loss) per common share: Diluted	$ (0.29)	$ 0.04
Weighted average number of shares outstanding during the period - Basic	14,816,586	11,937,530
Weighted average number of shares outstanding during the period - Diluted	14,816,586	12,809,335

XML 17 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash flows provided by (used in) operating activities:
Net income (loss)	$ (4,244,011)	$ 1,007,009
Adjustments to reconcile net income (loss) to net cash provided by operations:
Depreciation and amortization	727,270	580,793
Non-cash gain on derivative instruments	(3,433,588)	0
Stock issued in lieu of cash compensation	9,310	300,000
Stock-based compensation	0	56,463
Bad debts	1,285	6,473,733
Accretion of beneficial conversion feature as interest	789,376	246,575
Accretion of debt discount	0	93,699
Gain on extinguishment of debt	(100,000)	0
Gain on legal settlement	0	(275,028)
Changes in operating assets and liabilities:
Accounts receivable	1,096,357	(12,843,394)
Prepaid expenses and other current assets	(126,863)	(16,935)
Security deposits	0	(39,222)
Accounts payable	(923,381)	(299,697)
Accrued expenses	(684,981)	417,102
Income tax assets and liabilities	(101,015)	457,769
Deferred tax liabilities	0	48,900
Net cash used in operating activities	(6,990,241)	(3,792,233)
Cash flows provided by (used in) investing activities:
Purchase of property and equipment	(19,002)	(213,142)
Net cash provided by investing activities	(19,002)	(213,142)
Cash flows provided by (used in) financing activities:
Dividends on Series B preferred stock	0	(523,050)
Proceeds from issuance of notes payable, related party	3,000,000	0
Proceeds from issuance of notes payable	5,000,000	3,030,000
Payments on notes payable	(4,600,000)	(60,000)
Payments on capital lease obligations	(323,181)	(197,316)
Net cash provided by financing activities	3,076,819	2,249,634
Net decrease in cash	(3,932,424)	(1,755,741)
Cash at beginning of period	8,833,230	2,406,246
Cash at end of period	4,900,806	650,505
Supplemental disclosure of cash flow information:
Cash paid for interest	520,000	160,835
Cash paid for taxes	0	470,831
Acquisition of noncontrolling interest in Biohealth Medical Laboratory, Inc.:
Deposits on acquisitions	0	259,875
Goodwill	0	(138,871)
Noncontrolling interest	$ 0	$ (121,004)

XML 18 R6.htm IDEA: XBRL DOCUMENT

1. Organization and Presentation

3 Months Ended

Mar. 31, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization and Presentation

Merger between the Company and Medytox Solutions, Inc.

Potential De-Listing of the Company’s Stock

Basis of Presentation

XML 19 R7.htm IDEA: XBRL DOCUMENT

2. Accounts Receivable

3 Months Ended

Mar. 31, 2016

Receivables [Abstract]

Accounts Receivable

Accounts receivable at March 31, 2016 and December 31, 2015 consisted of the following:

	March 31,			December 31,
	2016			2015
Accounts receivable - clinical laboratory operations	$	96,227,506		$	105,332,339
Accounts receivable - supportive software solutions		329,395			569,351

Total accounts receivable		96,556,901			105,901,690
Less:
Allowance for discounts		(89,328,698	)		(97,577,130	)
Allowance for bad debts		(176,361	)		(175,076	)

Accounts receivable, net	$	7,051,842		$	8,149,484

- Definition

The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.

+ References + Details

XML 20 R8.htm IDEA: XBRL DOCUMENT

3. Long-Lived Assets

3 Months Ended

Mar. 31, 2016

Property, Plant and Equipment [Abstract]

Long-Lived Assets

Property and equipment at March 31, 2016 and December 31, 2015 consisted of the following:

	March 31,			December 31,
	2016			2015
Medical equipment	$	922,551		$	991,903
Equipment		577,316			547,555
Equipment under capital leases		5,663,333			5,663,332
Furniture		561,688			560,400
Leasehold improvements		1,776,957			1,760,125
Vehicles		196,534			196,534
Computer equipment		753,225			661,234
Software		1,837,174			1,878,848

		12,288,778			12,259,931
Less accumulated depreciation		(5,838,906	)		(5,111,636	)
Property and equipment, net	$	6,449,872		$	7,148,295

Depreciation of property and equipment was $727,270 and $580,793 for the three months ended March 31, 2016 and 2015, respectively.

Management periodically reviews the valuation of long-lived assets for potential impairments. Management has not recognized an impairment of these assets to date.

XML 21 R9.htm IDEA: XBRL DOCUMENT

4. Notes Payable

3 Months Ended

Mar. 31, 2016

Debt Disclosure [Abstract]

Notes Payable

The Company and its subsidiaries are party to a number of loans with affiliates and unrelated parties. At March 31, 2016 and December 31, 2015, notes payable consisted of the following:

Notes Payable – Third Parties

	March 31, 2016
	Face Value		Unamortized			Fair Value of		Net Value
	of Note		Discount			Derivatives		of Note
Loan payable under prepaid forward purchase contract in the amount of $5,000,000, at 20% interest, with no payments of interest or principal through March 30, 2017. All outstanding amounts are due March 30, 2017.	$	5,000,000	$	–		$	–	$	5,000,000

Loan payable to TCA Global Master Fund, LP in the amount of $3,000,000, at 16% interest, with interest only payments monthly through September 11, 2016. Principal and interest payments are due monthly from October 11, 2016 through September 11, 2017.		3,000,000		(305,188	)		130,849		2,825,661

Loan payable to CommerceNet in the amount of $250,000 at 1.06% interest, increasing to 6% after two years. Principal and interest payments are made annually from July 12, 2015 through July 12, 2017.		170,806		–			–		170,806

Loan payable to Jay Tenebaum in the amount of $250,000 at 1.06% interest, increasing to 6% after two years. Principal and interest payments are made annually from July 12, 2015 through July 12, 2017.		170,806		–			–		170,806

	$	8,341,612	$	(305,188	)	$	130,849		8,167,273

Less current portion									(5,269,031	)

Notes payable, net of current portion								$	2,898,242

	December 31, 2015
	Face Value		Unamortized			Fair Value of		Net Value
	of Note		Discount			Derivatives		of Note
Loan payable to former shareholder of Epinex Diagnostics Laboratories, Inc. in the amount of $400,000, at 0% interest, with principal payments of $100,000 due in periodic installments from November 26, 2014 through February 26, 2016. Amount recorded is net of imputed discount of $1,775 at December 31, 2015.	$	100,000	$	(1,775	)	$	–	$	98,225

Loan payable to TCA Global Master Fund, LP in the amount of $3,000,000, at 16% interest, with interest only payments monthly through September 11, 2016. Principal and interest payments are due monthly from October 11, 2016 through September 11, 2017.		3,000,000		(453,025	)		186,117		2,733,092

Loan payable to CommerceNet in the amount of $250,000 at 1.06% interest, increasing to 6% after two years. Principal and interest payments are made annually from July 12, 2015 through July 12, 2017.		170,806		–			–		170,806

Loan payable to Jay Tenebaum in the amount of $250,000 at 1.06% interest, increasing to 6% after two years. Principal and interest payments are made annually from July 12, 2015 through July 12, 2017.		170,806		–			–		170,806

	$	3,441,612	$	(454,800	)	$	186,117		3,172,929

Less current portion									(269,031	)

Notes payable, net of current portion								$	2,903,898

Notes Payable – Related Parties

	March 31, 2016
	Face Value		Unamortized			Fair Value of		Net Value
	of Note		Discount			Derivatives		of Note
Convertible debenture dated December 31, 2014 in the amount of $3,000,000 which bears interest at 10% and is due December 31, 2016. The note provides the lender, D&D Funding II, LLC, the option to convert the note into the Company's common stock at a 25% discount to the average trading price (as defined in the note agreement) for the ten consecutive trading days prior to the conversion date.	$	3,000,000	$	(1,588,495	)	$	2,263,237	$	3,674,742

Loan payable to Alcimede, LLC in the amount of $3,000,000, at 6% interest, with one payment of $3,000,000, plus interest, due on February 2, 2017. (On June 29, 2015, Alcimede exercised options to purchase 1,000,000 shares for $2,500,000, which reduced the loan.)	$	500,000		–			–	$	500,000

Current portion of notes payable, related party	$	3,500,000	$	(1,588,495	)	$	2,263,237	$	4,174,742

	December 31, 2015
	Face Value		Unamortized			Fair Value of		Net Value
	of Note		Discount			Derivatives		of Note
Convertible debenture dated December 31, 2014 in the amount of $3,000,000 which bears interest at 10% and is due December 31, 2016. The note provides the lender, D&D Funding II, LLC, the option to convert the note into the Company's common stock at a 25% discount to the average trading price (as defined in the note agreement) for the ten consecutive trading days prior to the conversion date.	$	3,000,000	$	(2,236,112	)	$	2,270,000	$	3,033,888

Loan payable to Alcimede, LLC in the amount of $3,000,000, at 6% interest, with one payment of $3,000,000, plus interest, due on February 2, 2016. (On June 29, 2015, Alcimede exercised options to purchase 1,000,000 shares for $2,500,000, which reduced the loan.)	$	500,000		–			–	$	500,000

Loan payable to Christopher Diamantis in the amount of $1,600,000. One payment of $1,600,000 due January 7, 2016 plus $100,000 of interest.	$	1,600,000		–			–	$	1,600,000

Current portion of notes payable, related party	$	5,100,000	$	(2,236,112	)	$	2,270,000	$	5,133,888

Convertible Debenture Dated December 31, 2014

On December 31, 2014, the Company borrowed $3,000,000 from D&D Funding II, LLC (“D&D”), Christopher Diamantis, a director of the Company, is the manager and 50% owner of D&D. In January 2016, the Company temporarily repaid $3,000,000 of the amounts due under the D&D note. In addition to the principal amount, the Company paid $300,000 in cash for interest for 2015. In March 2016, the Company re-borrowed 100% of the principal amount repaid in January 2016. This note is convertible into the Company’s Common Stock at a 25% discount to the trailing ten day average closing price at any time prior to the repayment. In the event of conversion, the holder of the note is also entitled to receive a number of warrants to purchase the Company’s Common Stock equal to the number of shares issued upon conversion with exercise prices equal to the trailing ten day average closing price of our Common Stock. These two features are derivative instruments that are re-valued quarterly and are reflected in the table above.

Prepaid Forward Purchase Contract

XML 22 R10.htm IDEA: XBRL DOCUMENT

5. Related Party Transactions

3 Months Ended

Mar. 31, 2016

Related Party Transactions

All of these transactions were completed at arm’s length at values commensurate with those of independent third parties.

XML 23 R11.htm IDEA: XBRL DOCUMENT

6. Capital Lease Obligations

3 Months Ended

Mar. 31, 2016

Debt Disclosure [Abstract]

Capital Lease Obligations

The Company leases various assets under capital leases expiring through 2020 as follows:

	March 31,			December 31,
	2016			2015
Medical equipment	$	5,663,333		$	5,663,332
Less accumulated depreciation		(2,443,384	)		(2,093,920	)

Net	$	3,219,949		$	3,569,412

Depreciation expense on assets under capital leases was $349,464 and $215,045 for the three months ended March 31, 2016 and 2015, respectively.

Aggregate future minimum rentals under capital leases are as follows:

December 31,
2016	$	1,217,765
2017		1,432,542
2018		845,330
2019		217,412
2020		32,611

Total		3,745,660

Less interest		350,962

Present value of minimum lease payments		3,394,698

Less current portion of capital lease obligations		1,323,708

Capital lease obligations, net of current portion	$	2,070,990

XML 24 R12.htm IDEA: XBRL DOCUMENT

7. Stockholders' Equity

3 Months Ended

Mar. 31, 2016

Equity [Abstract]

Stockholders' Equity

Preferred Stock

During the three months ended March 31, 2016, Series C preferred shareholders converted a total of 182 shares of Series C preferred stock into 117,420 shares of Common Stock.

Common Stock

Stock Options

During the three months ended March 31, 2016 and 2015, no stock options were granted or forfeited.

Basic and Diluted Income per Share

	Three Months Ended March 31,
	2016			2015
Basic:
Numerator - net income (loss) available to common stockholders	$	(4,244,011	)		483,959
Denominator - weighted-average shares outstanding		14,816,586			11,937,530

Net income (loss) per share - Basic	$	(0.29	)	$	0.04

Diluted:
Numerator:
Net income (loss) available to common stockholders	$	(4,244,011	)	$	483,959
Interest expense on convertible debt, net of taxes		–			46,912
		(4,244,011	)		530,871

Denominator:
Weighted-average shares outstanding		14,816,586			11,937,530
Weighted-average equivalent shares options and warrants		–			354,901
Weighted-average equivalent shares from convertible debt		–			409,638
Weighted-average equivalent shares from Series C convertible preferred stock		–			–
Weighted-average equivalent shares from Series D convertible preferred stock		–			73,643
Weighted-average equivalent shares from Series E convertible preferred stock		–			33,623
		14,816,586			12,809,335

Net income (loss) per share - Diluted	$	(0.29	)	$	0.04

	March 31,		March 31,
	2016		2015
Stock options outstanding		1,822,675		9,923,474
Warrants outstanding		6,898,560		–
Convertible debt		8,791,343		–
Convertible preferred stock		11,422,977		–

		28,935,555		9,923,474

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

XML 25 R13.htm IDEA: XBRL DOCUMENT

8. Income Taxes

3 Months Ended

Mar. 31, 2016

Income Tax Disclosure [Abstract]

Income Taxes

Changes to the effective tax rates relate primarily to the recognition of a valuation allowance on 100% of net deferred tax assets for the three months ended March 31, 2016.

The table below presents a reconciliation of statutory income tax rates to our effective rates:

	Three Months Ended March 31,
	2016		2015
Expected federal income tax at statutory rate		35.0%		34.0%
State income taxes, net of federal deduction		2.1%		4.7%
Permanent differences		-0.1%		10.6%
Change in valuation allowance		-37.0%		0.0%

		0.0%		49.3%

XML 26 R14.htm IDEA: XBRL DOCUMENT

9. Business Combinations

3 Months Ended

Mar. 31, 2016

Business Combinations [Abstract]

Business Combinations

Completion of Merger

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1524-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4922-128472

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4934-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=73530397&loc=d3e4926-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=73530397&loc=SL65897772-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65885119&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

XML 27 R15.htm IDEA: XBRL DOCUMENT

10. Commitments and Contingencies

3 Months Ended

Mar. 31, 2016

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Legal Matters

XML 28 R16.htm IDEA: XBRL DOCUMENT

11. Segment Reporting

3 Months Ended

Mar. 31, 2016

Segment Reporting [Abstract]

Segment Reporting

Selected financial information for the Company’s operating segments is as follows:

	Three Months Ended March 31,
	2016			2015
Net revenues - External
Clinical Laboratory Operations	$	1,465,137		$	13,499,803
Supportive Software Solutions		230,026			148,979
Decision Support and Informatics Operations		183,650			–
Corporate		–			–
Eliminations		–			–
	$	1,878,813		$	13,648,782
Net revenues - Inter Segment
Clinical Laboratory Operations	$	–		$	–
Supportive Software Solutions		296,348			384,108
Decision Support and Informatics Operations		–			–
Corporate		–			–
Eliminations		–			–
	$	296,348		$	384,108
Income (loss) from operations
Clinical Laboratory Operations	$	(2,650,540	)	$	5,065,421
Supportive Software Solutions		(1,313,313	)		(1,357,989	)
Decision Support and Informatics Operations		(881,566	)		–
Corporate		(1,952,437	)		(1,521,117	)
Eliminations		33,660			28,246
	$	(6,764,196	)	$	2,214,561
Depreciation and amortization
Clinical Laboratory Operations	$	581,101		$	447,325
Supportive Software Solutions		164,428			160,356
Decision Support and Informatics Operations		14,527			–
Corporate		875			1,358
Eliminations		(33,661	)		(28,246	)
	$	727,270		$	580,793
Capital expenditures
Clinical Laboratory Operations	$	16,885		$	187,885
Supportive Software Solutions		2,117			25,257
Decision Support and Informatics Operations		–			–
Corporate		–			–
Eliminations		–			–
	$	19,002		$	213,142

	March 31,			December 31,
	2016			2015
Total assets
Clinical Laboratory Operations	$	13,357,738		$	15,152,583
Supportive Software Solutions		2,677,943			2,896,473
Decision Support and Informatics Operations		3,714,571			4,307,053
Corporate		9,046,263			12,711,284
Eliminations		(6,327,245	)		(7,095,520	)
	$	22,469,270		$	27,971,873

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=68060357&loc=d3e8906-108599

+ Details

XML 29 R17.htm IDEA: XBRL DOCUMENT

12. Subsequent Events

3 Months Ended

Mar. 31, 2016

Subsequent Events [Abstract]

Subsequent Events

XML 30 R18.htm IDEA: XBRL DOCUMENT

2. Accounts Receivable (Tables)

3 Months Ended

Mar. 31, 2016

Receivables [Abstract]

Schedule of accounts receivable

	March 31,			December 31,
	2016			2015
Accounts receivable - clinical laboratory operations	$	96,227,506		$	105,332,339
Accounts receivable - supportive software solutions		329,395			569,351

Total accounts receivable		96,556,901			105,901,690
Less:
Allowance for discounts		(89,328,698	)		(97,577,130	)
Allowance for bad debts		(176,361	)		(175,076	)

Accounts receivable, net	$	7,051,842		$	8,149,484

XML 31 R19.htm IDEA: XBRL DOCUMENT

3. Long-Lived Assets (Tables)

3 Months Ended

Mar. 31, 2016

Property, Plant and Equipment [Abstract]

Schedule of property and equipment

	March 31,			December 31,
	2016			2015
Medical equipment	$	922,551		$	991,903
Equipment		577,316			547,555
Equipment under capital leases		5,663,333			5,663,332
Furniture		561,688			560,400
Leasehold improvements		1,776,957			1,760,125
Vehicles		196,534			196,534
Computer equipment		753,225			661,234
Software		1,837,174			1,878,848

		12,288,778			12,259,931
Less accumulated depreciation		(5,838,906	)		(5,111,636	)
Property and equipment, net	$	6,449,872		$	7,148,295

XML 32 R20.htm IDEA: XBRL DOCUMENT

4. Notes Payable (Tables)

3 Months Ended

Mar. 31, 2016

Debt Disclosure [Abstract]

Schedule of notes payable

	March 31, 2016
	Face Value		Unamortized			Fair Value of		Net Value
	of Note		Discount			Derivatives		of Note
Loan payable under prepaid forward purchase contract in the amount of $5,000,000, at 20% interest, with no payments of interest or principal through March 30, 2017. All outstanding amounts are due March 30, 2017.	$	5,000,000	$	–		$	–	$	5,000,000

Loan payable to TCA Global Master Fund, LP in the amount of $3,000,000, at 16% interest, with interest only payments monthly through September 11, 2016. Principal and interest payments are due monthly from October 11, 2016 through September 11, 2017.		3,000,000		(305,188	)		130,849		2,825,661

Loan payable to CommerceNet in the amount of $250,000 at 1.06% interest, increasing to 6% after two years. Principal and interest payments are made annually from July 12, 2015 through July 12, 2017.		170,806		–			–		170,806

Loan payable to Jay Tenebaum in the amount of $250,000 at 1.06% interest, increasing to 6% after two years. Principal and interest payments are made annually from July 12, 2015 through July 12, 2017.		170,806		–			–		170,806

	$	8,341,612	$	(305,188	)	$	130,849		8,167,273

Less current portion									(5,269,031	)

Notes payable, net of current portion								$	2,898,242

	December 31, 2015
	Face Value		Unamortized			Fair Value of		Net Value
	of Note		Discount			Derivatives		of Note
Loan payable to former shareholder of Epinex Diagnostics Laboratories, Inc. in the amount of $400,000, at 0% interest, with principal payments of $100,000 due in periodic installments from November 26, 2014 through February 26, 2016. Amount recorded is net of imputed discount of $1,775 at December 31, 2015.	$	100,000	$	(1,775	)	$	–	$	98,225

Loan payable to TCA Global Master Fund, LP in the amount of $3,000,000, at 16% interest, with interest only payments monthly through September 11, 2016. Principal and interest payments are due monthly from October 11, 2016 through September 11, 2017.		3,000,000		(453,025	)		186,117		2,733,092

Loan payable to CommerceNet in the amount of $250,000 at 1.06% interest, increasing to 6% after two years. Principal and interest payments are made annually from July 12, 2015 through July 12, 2017.		170,806		–			–		170,806

Loan payable to Jay Tenebaum in the amount of $250,000 at 1.06% interest, increasing to 6% after two years. Principal and interest payments are made annually from July 12, 2015 through July 12, 2017.		170,806		–			–		170,806

	$	3,441,612	$	(454,800	)	$	186,117		3,172,929

Less current portion									(269,031	)

Notes payable, net of current portion								$	2,903,898

Schedule of notes payable - related parties

	March 31, 2016
	Face Value		Unamortized			Fair Value of		Net Value
	of Note		Discount			Derivatives		of Note
Convertible debenture dated December 31, 2014 in the amount of $3,000,000 which bears interest at 10% and is due December 31, 2016. The note provides the lender, D&D Funding II, LLC, the option to convert the note into the Company's common stock at a 25% discount to the average trading price (as defined in the note agreement) for the ten consecutive trading days prior to the conversion date.	$	3,000,000	$	(1,588,495	)	$	2,263,237	$	3,674,742

Loan payable to Alcimede, LLC in the amount of $3,000,000, at 6% interest, with one payment of $3,000,000, plus interest, due on February 2, 2017. (On June 29, 2015, Alcimede exercised options to purchase 1,000,000 shares for $2,500,000, which reduced the loan.)	$	500,000		–			–	$	500,000

Current portion of notes payable, related party	$	3,500,000	$	(1,588,495	)	$	2,263,237	$	4,174,742

	December 31, 2015
	Face Value		Unamortized			Fair Value of		Net Value
	of Note		Discount			Derivatives		of Note
Convertible debenture dated December 31, 2014 in the amount of $3,000,000 which bears interest at 10% and is due December 31, 2016. The note provides the lender, D&D Funding II, LLC, the option to convert the note into the Company's common stock at a 25% discount to the average trading price (as defined in the note agreement) for the ten consecutive trading days prior to the conversion date.	$	3,000,000	$	(2,236,112	)	$	2,270,000	$	3,033,888

Loan payable to Alcimede, LLC in the amount of $3,000,000, at 6% interest, with one payment of $3,000,000, plus interest, due on February 2, 2016. (On June 29, 2015, Alcimede exercised options to purchase 1,000,000 shares for $2,500,000, which reduced the loan.)	$	500,000		–			–	$	500,000

Loan payable to Christopher Diamantis in the amount of $1,600,000. One payment of $1,600,000 due January 7, 2016 plus $100,000 of interest.	$	1,600,000		–			–	$	1,600,000

Current portion of notes payable, related party	$	5,100,000	$	(2,236,112	)	$	2,270,000	$	5,133,888

XML 33 R21.htm IDEA: XBRL DOCUMENT

6. Capital Lease Obligations (Tables)

3 Months Ended

Mar. 31, 2016

Debt Disclosure [Abstract]

Schedule of capital leases

	March 31,			December 31,
	2016			2015
Medical equipment	$	5,663,333		$	5,663,332
Less accumulated depreciation		(2,443,384	)		(2,093,920	)

Net	$	3,219,949		$	3,569,412

Aggregate future minimum rentals under capital leases

December 31,
2016	$	1,217,765
2017		1,432,542
2018		845,330
2019		217,412
2020		32,611

Total		3,745,660

Less interest		350,962

Present value of minimum lease payments		3,394,698

Less current portion of capital lease obligations		1,323,708

Capital lease obligations, net of current portion	$	2,070,990

XML 34 R22.htm IDEA: XBRL DOCUMENT

7. Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2016

Equity [Abstract]

Basic and Diluted Income Per Share

	Three Months Ended March 31,
	2016			2015
Basic:
Numerator - net income (loss) available to common stockholders	$	(4,244,011	)		483,959
Denominator - weighted-average shares outstanding		14,816,586			11,937,530

Net income (loss) per share - Basic	$	(0.29	)	$	0.04

Diluted:
Numerator:
Net income (loss) available to common stockholders	$	(4,244,011	)	$	483,959
Interest expense on convertible debt, net of taxes		–			46,912
		(4,244,011	)		530,871

Denominator:
Weighted-average shares outstanding		14,816,586			11,937,530
Weighted-average equivalent shares options and warrants		–			354,901
Weighted-average equivalent shares from convertible debt		–			409,638
Weighted-average equivalent shares from Series C convertible preferred stock		–			–
Weighted-average equivalent shares from Series D convertible preferred stock		–			73,643
Weighted-average equivalent shares from Series E convertible preferred stock		–			33,623
		14,816,586			12,809,335

Net income (loss) per share - Diluted	$	(0.29	)	$	0.04

Antidilutive Securities

	March 31,		March 31,
	2016		2015
Stock options outstanding		1,822,675		9,923,474
Warrants outstanding		6,898,560		–
Convertible debt		8,791,343		–
Convertible preferred stock		11,422,977		–

		28,935,555		9,923,474

XML 35 R23.htm IDEA: XBRL DOCUMENT

8. Income Taxes (Tables)

3 Months Ended

Mar. 31, 2016

Income Tax Disclosure [Abstract]

Reconciliation of the statutory federal income tax rate

	Three Months Ended March 31,
	2016		2015
Expected federal income tax at statutory rate		35.0%		34.0%
State income taxes, net of federal deduction		2.1%		4.7%
Permanent differences		-0.1%		10.6%
Change in valuation allowance		-37.0%		0.0%

		0.0%		49.3%

XML 36 R24.htm IDEA: XBRL DOCUMENT

11. Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2016

Segment Reporting [Abstract]

Segment information

	Three Months Ended March 31,
	2016			2015
Net revenues - External
Clinical Laboratory Operations	$	1,465,137		$	13,499,803
Supportive Software Solutions		230,026			148,979
Decision Support and Informatics Operations		183,650			–
Corporate		–			–
Eliminations		–			–
	$	1,878,813		$	13,648,782
Net revenues - Inter Segment
Clinical Laboratory Operations	$	–		$	–
Supportive Software Solutions		296,348			384,108
Decision Support and Informatics Operations		–			–
Corporate		–			–
Eliminations		–			–
	$	296,348		$	384,108
Income (loss) from operations
Clinical Laboratory Operations	$	(2,650,540	)	$	5,065,421
Supportive Software Solutions		(1,313,313	)		(1,357,989	)
Decision Support and Informatics Operations		(881,566	)		–
Corporate		(1,952,437	)		(1,521,117	)
Eliminations		33,660			28,246
	$	(6,764,196	)	$	2,214,561
Depreciation and amortization
Clinical Laboratory Operations	$	581,101		$	447,325
Supportive Software Solutions		164,428			160,356
Decision Support and Informatics Operations		14,527			–
Corporate		875			1,358
Eliminations		(33,661	)		(28,246	)
	$	727,270		$	580,793
Capital expenditures
Clinical Laboratory Operations	$	16,885		$	187,885
Supportive Software Solutions		2,117			25,257
Decision Support and Informatics Operations		–			–
Corporate		–			–
Eliminations		–			–
	$	19,002		$	213,142

	March 31,			December 31,
	2016			2015
Total assets
Clinical Laboratory Operations	$	13,357,738		$	15,152,583
Supportive Software Solutions		2,677,943			2,896,473
Decision Support and Informatics Operations		3,714,571			4,307,053
Corporate		9,046,263			12,711,284
Eliminations		(6,327,245	)		(7,095,520	)
	$	22,469,270		$	27,971,873

XML 37 R25.htm IDEA: XBRL DOCUMENT

1. Organization and Presentation (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Proceeds from pledged receivables	$ 5,000,000
Income tax receivable	$ 2,516,028	$ 2,415,013

XML 38 R26.htm IDEA: XBRL DOCUMENT

2. Accounts Receivable (Details - Accounts receivable) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Accounts receivable, gross	$ 96,556,901	$ 105,901,690
Less: Allowance for discounts	(89,328,698)	(97,577,130)
Less: Allowance for bad debts	(176,361)	(175,076)
Accounts receivable, net	7,051,842	8,149,484
Clinical Laboratory Operations [Member]
Accounts receivable, gross	96,227,506	105,332,339
Supportive Software Solutions [Member]
Accounts receivable, gross	$ 329,395	$ 569,351

XML 39 R27.htm IDEA: XBRL DOCUMENT

3. Long-Lived Assets (Details - Equipment) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Property and equipment, gross	$ 12,288,778	$ 12,359,931
Accumulated depreciation	(5,838,906)	(5,111,636)
Property and equipment, net	6,449,872	7,148,295
Medical equipment [Member]
Property and equipment, gross	922,551	991,903
Equipment [Member]
Property and equipment, gross	577,316	547,555
Assets Held Under Capital Leases [Member]
Property and equipment, gross	5,663,333	5,663,332
Furniture [Member]
Property and equipment, gross	561,688	560,400
Leasehold Improvements [Member]
Property and equipment, gross	1,776,957	1,760,125
Vehicles [Member]
Property and equipment, gross	196,534	196,534
Computer Equipment [Member]
Property and equipment, gross	753,225	661,234
Software [Member]
Property and equipment, gross	$ 1,837,174	$ 1,878,848

XML 40 R28.htm IDEA: XBRL DOCUMENT

3. Long-Lived Assets (Details Narrative) - USD ($)	3 Months Ended
3. Long-Lived Assets (Details Narrative) - USD ($)	Mar. 31, 2016	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Depreciation	$ 727,270	$ 580,793

XML 41 R29.htm IDEA: XBRL DOCUMENT

4. Notes Payable (Details-Notes Payable) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Less: current portion	$ (5,269,031)	$ (269,031)
Notes payable, net of current portion	2,898,242	2,903,898
Notes Payable - Third Parties [Member]
Face value of note	8,341,612	3,441,612
Unamortized discount	(305,188)	(454,800)
Fair value of derivatives	130,849	186,117
Notes payable, net	8,167,273	3,172,929
Note payable 1 [Member]
Face value of note		100,000
Unamortized discount		(1,775)
Fair value of derivatives		0
Notes payable, net		98,225
Note payable 2 [Member]
Face value of note	3,000,000	3,000,000
Unamortized discount	(305,188)	(453,025)
Fair value of derivatives	130,849	186,117
Notes payable, net	2,825,661	2,733,092
Note payable 3 [Member]
Face value of note	170,806	170,806
Unamortized discount	0	0
Fair value of derivatives	0	0
Notes payable, net	170,806	170,806
Note payable 4 [Member]
Face value of note	170,806
Unamortized discount	0
Fair value of derivatives	0
Notes payable, net	170,806
Note payable 5 [Member]
Face value of note	5,000,000	170,806
Unamortized discount	0	0
Fair value of derivatives	0	0
Notes payable, net	$ 5,000,000	$ 170,806

XML 42 R30.htm IDEA: XBRL DOCUMENT

4. Notes Payable (Details-Notes Payable Related Party) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Notes payable related parties	$ 4,174,742	$ 5,133,888
Notes payable - related party [Member]
Face value of note	3,500,000	5,100,000
Unamortized discount	(1,588,495)	(2,236,112)
Fair value of derivatives	2,263,237	2,270,000
Notes payable related parties	4,174,742	5,133,888
Notes payable - related party [Member] \| Notes payable - related party 1 [Member]
Face value of note	3,000,000	3,000,000
Unamortized discount	(1,588,495)	(2,236,112)
Fair value of derivatives	2,263,237	2,270,000
Notes payable related parties	3,674,742	3,033,888
Notes payable - related party [Member] \| Notes payable - related party 2 [Member]
Face value of note	500,000	500,000
Notes payable related parties	$ 500,000	500,000
Notes payable - related party [Member] \| Notes payable - related party 3 [Member]
Face value of note		1,600,000
Notes payable related parties		$ 1,600,000

XML 43 R31.htm IDEA: XBRL DOCUMENT

4. Notes Payable (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
4. Notes Payable (Details Narrative) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Note payable 5 [Member]
Debt original face amount	$ 5,000,000
Interest rate	20.00%
Maturity date	Mar. 30, 2017
Note payable 2 [Member]
Debt original face amount	$ 3,000,000
Interest rate	16.00%
Maturity date	Sep. 11, 2017
Note payable 3 [Member]
Debt original face amount	$ 250,000
Interest rate	1.06%
Maturity date	Jul. 12, 2017
Note payable 4 [Member]
Debt original face amount	$ 250,000
Interest rate	106.00%
Maturity date	Jul. 12, 2017
Note payable 1 [Member]
Debt original face amount		$ 400,000
Interest rate		0.00%
Maturity date		Dec. 31, 2015
Imputed discount		$ 1,775
Notes payable - related party 1 [Member] \| Notes payable - related party [Member]
Debt original face amount	$ 3,000,000
Interest rate	10.00%
Maturity date	Dec. 31, 2016
Notes payable - related party 2 [Member] \| Notes payable - related party [Member]
Debt original face amount	$ 3,000,000
Interest rate	6.00%
Maturity date	Feb. 02, 2016
Notes payable - related party 3 [Member] \| Notes payable - related party [Member]
Debt original face amount		$ 1,600,000
Maturity date	Jan. 07, 2016

XML 44 R32.htm IDEA: XBRL DOCUMENT

5. Related Party Transactions (Details Narrative) - USD ($)	3 Months Ended		4 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Apr. 30, 2016
Proceeds from related party	$ 3,000,000	$ 0
D & D Funding [Member]
Repayment of note payable	3,000,000		$ 2,250,000
Payment of 2015 interest expense	300,000
Proceeds from related party	3,000,000
Alcimede [Member]
Consulting fees paid	$ 96,750	$ 85,905

XML 45 R33.htm IDEA: XBRL DOCUMENT

6. Capital Lease Obligations (Details-Capital leased assets) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Capital Lease Obligations [Abstract]
Medical equipment	$ 5,663,333	$ 5,663,332
Less accumulated depreciation	(2,443,384)	(2,093,920)
Capital lease obligations	$ 3,219,949	$ 3,569,412

XML 46 R34.htm IDEA: XBRL DOCUMENT

6. Capital Lease Obligations (Details-Future payments) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
December 31,
2016	$ 1,217,765
2017	1,432,542
2018	845,330
2019	217,412
2020	32,611
Total	3,745,660
Less interest:	350,962
Present value of minimum lease payments	3,394,698
Less current portion of capital lease obligations	1,323,708	$ 1,323,708
Capital lease obligations, net of current portion	$ 2,070,990	$ 2,394,171

XML 47 R35.htm IDEA: XBRL DOCUMENT

6. Capital Lease Obligations (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Capital Lease Obligations Details Narrative
Depreciation expense on capital leases	$ 349,464	$ 215,045

XML 48 R36.htm IDEA: XBRL DOCUMENT

7. Stockholders Equity Earnings (Details-EPS) - USD ($)	3 Months Ended
7. Stockholders Equity Earnings (Details-EPS) - USD ($)	Mar. 31, 2016	Mar. 31, 2015
Basic:
Net income (loss) available to common stockholders	$ (4,244,011)	$ 483,959
Weighted average number of shares outstanding	14,816,586	11,937,530
Net income (loss) per share - Basic	$ (.29)	$ .04
Diluted:
Net income (loss) available to common stockholders	$ (4,244,011)	$ 483,959
Interest expense on convertible debt, net of taxes	0	46,912
Diluted net income	$ (4,244,011)	$ 530,871
Weighted-average shares outstanding	14,816,586	11,937,530
Weighted-average equivalent shares options and warrants	0	354,901
Weighted-average equivalent shares from convertible debt	0	409,638
Diluted Shares Outstanding	14,816,586	12,809,335
Net income (loss) per share - Diluted	$ (0.29)	$ 0.04
Series C Preferred Stock [Member]
Diluted:
Weighted-average equivalent shares from convertible preferred stock	0	0
Series D Preferred Stock [Member]
Diluted:
Weighted-average equivalent shares from convertible preferred stock	0	73,643
Series E Preferred Stock [Member]
Diluted:
Weighted-average equivalent shares from convertible preferred stock	0	33,623

XML 49 R37.htm IDEA: XBRL DOCUMENT

7. Stockholders' Equity (Details - Antidilutive shares) - shares	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Antidilutive securities	28,935,555	9,923,474
Stock Options [Member]
Antidilutive securities	1,822,675	9,923,474
Warrant [Member]
Antidilutive securities	6,898,560	0
Convertible Debt [Member]
Antidilutive securities	8,791,343	0
Convertible Preferred Stock [Member]
Antidilutive securities	11,422,977	0

XML 50 R38.htm IDEA: XBRL DOCUMENT

7. Stockholders' Equity (Details Narrative) - USD ($)	3 Months Ended
7. Stockholders' Equity (Details Narrative) - USD ($)	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Dividends earned	$ 0	$ 523,050
Accrued dividends	$ 1,684,148		$ 2,099,148
Stock options granted	0	0
Stock options forfeited	0	0
Consultant [Member]
Stock issued for services, shares issued	13,300
Stock issued for services, value	$ 9,310
Series C Preferred Stock [Member]
Preferred stock converted into common, preferred shares converted	182
Preferred stock converted into common, common shares issued	117,420

XML 51 R39.htm IDEA: XBRL DOCUMENT

8. Income Taxes (Details-Effective income tax rate)	3 Months Ended
8. Income Taxes (Details-Effective income tax rate)	Mar. 31, 2016	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Expected federal income tax at statutory rate	35.00%	34.00%
State income taxes, net of federal deduction	2.10%	4.70%
Permanent differences	(0.10%)	10.60%
Change in valuation allowance	37.00%	0.00%
Income tax provision (benefit)	0.00%	49.30%

XML 52 R40.htm IDEA: XBRL DOCUMENT

8. Income Taxes (Details Narrative) - USD ($)	3 Months Ended
8. Income Taxes (Details Narrative) - USD ($)	Mar. 31, 2016	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Income tax expense	$ 0	$ 977,500

XML 53 R41.htm IDEA: XBRL DOCUMENT

11. Segment Reporting (Details-Operations) - USD ($)	3 Months Ended
11. Segment Reporting (Details-Operations) - USD ($)	Mar. 31, 2016	Mar. 31, 2015
Net revenues - External	$ 1,878,813	$ 13,648,782
Net revenues - Inter Segment	296,348	384,108
Income (loss) from operations	(6,764,196)	2,214,561
Depreciation and amortization	727,270	580,793
Capital expenditures	19,002	213,142
Eliminations [Member]
Net revenues - External	0	0
Net revenues - Inter Segment	0	0
Income (loss) from operations	33,660	28,246
Depreciation and amortization	(33,661)	(28,246)
Capital expenditures	0	0
Clinical Laboratory Operations [Member]
Net revenues - External	1,465,137	13,499,803
Net revenues - Inter Segment	0	0
Income (loss) from operations	(2,650,540)	5,065,421
Depreciation and amortization	581,101	447,325
Capital expenditures	16,885	187,885
Supportive Software Solutions [Member]
Net revenues - External	230,026	148,979
Net revenues - Inter Segment	296,348	384,108
Income (loss) from operations	(1,313,313)	(1,357,989)
Depreciation and amortization	164,428	160,356
Capital expenditures	2,117	25,257
Decision Support and Informatics Operations [Member]
Net revenues - External	183,650	0
Net revenues - Inter Segment	0	0
Income (loss) from operations	(881,566)	0
Depreciation and amortization	14,527	0
Capital expenditures	0	0
Corporate [Member]
Net revenues - External	0	0
Net revenues - Inter Segment	0	0
Income (loss) from operations	(1,952,437)	(1,521,117)
Depreciation and amortization	875	1,358
Capital expenditures	$ 0	$ 0

XML 54 R42.htm IDEA: XBRL DOCUMENT

11. Segment Reporting (Details-Assets) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Total assets	$ 22,469,270	$ 27,971,873
Eliminations [Member]
Total assets	(7,095,520)	(6,327,245)
Clinical Laboratory Operations [Member]
Total assets	13,357,738	15,152,583
Supportive Software Solutions [Member]
Total assets	2,677,943	2,896,473
Decision Support and Informatics Operations [Member]
Total assets	3,714,571	4,307,053
Corporate [Member]
Total assets	$ 9,046,263	$ 12,711,284

EXCEL 55 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 56 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 57 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 59 FilingSummary.xml IDEA: XBRL DOCUMENT 3.4.0.3 html 97 171 1 false 36 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://rennova.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://rennova.com/role/BalanceSheets Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://rennova.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://rennova.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://rennova.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Disclosure - 1. Organization and Presentation Sheet http://rennova.com/role/OrganizationAndPresentation 1. Organization and Presentation Notes 6 false false R7.htm 00000007 - Disclosure - 2. Accounts Receivable Sheet http://rennova.com/role/AccountsReceivable 2. Accounts Receivable Notes 7 false false R8.htm 00000008 - Disclosure - 3. Long-Lived Assets Sheet http://rennova.com/role/Long-livedAssets 3. Long-Lived Assets Notes 8 false false R9.htm 00000009 - Disclosure - 4. Notes Payable Notes http://rennova.com/role/NotesPayable 4. Notes Payable Notes 9 false false R10.htm 00000010 - Disclosure - 5. Related Party Transactions Sheet http://rennova.com/role/RelatedPartyTransactions 5. Related Party Transactions Notes 10 false false R11.htm 00000011 - Disclosure - 6. Capital Lease Obligations Sheet http://rennova.com/role/CapitalLeaseObligations 6. Capital Lease Obligations Notes 11 false false R12.htm 00000012 - Disclosure - 7. Stockholders' Equity Sheet http://rennova.com/role/StockholdersEquity 7. Stockholders' Equity Notes 12 false false R13.htm 00000013 - Disclosure - 8. Income Taxes Sheet http://rennova.com/role/IncomeTaxes 8. Income Taxes Notes 13 false false R14.htm 00000014 - Disclosure - 9. Business Combinations Sheet http://rennova.com/role/BusinessCombinations 9. Business Combinations Notes 14 false false R15.htm 00000015 - Disclosure - 10. Commitments and Contingencies Sheet http://rennova.com/role/CommitmentsAndContingencies 10. Commitments and Contingencies Notes 15 false false R16.htm 00000016 - Disclosure - 11. Segment Reporting Sheet http://rennova.com/role/SegmentReporting 11. Segment Reporting Notes 16 false false R17.htm 00000017 - Disclosure - 12. Subsequent Events Sheet http://rennova.com/role/SubsequentEvents 12. Subsequent Events Notes 17 false false R18.htm 00000018 - Disclosure - 2. Accounts Receivable (Tables) Sheet http://rennova.com/role/AccountsReceivableTables 2. Accounts Receivable (Tables) Tables http://rennova.com/role/AccountsReceivable 18 false false R19.htm 00000019 - Disclosure - 3. Long-Lived Assets (Tables) Sheet http://rennova.com/role/Long-livedAssetsTables 3. Long-Lived Assets (Tables) Tables http://rennova.com/role/Long-livedAssets 19 false false R20.htm 00000020 - Disclosure - 4. Notes Payable (Tables) Notes http://rennova.com/role/NotesPayableTables 4. Notes Payable (Tables) Tables http://rennova.com/role/NotesPayable 20 false false R21.htm 00000021 - Disclosure - 6. Capital Lease Obligations (Tables) Sheet http://rennova.com/role/CapitalLeaseObligationsTables 6. Capital Lease Obligations (Tables) Tables http://rennova.com/role/CapitalLeaseObligations 21 false false R22.htm 00000022 - Disclosure - 7. Stockholders' Equity (Tables) Sheet http://rennova.com/role/StockholdersEquityTables 7. Stockholders' Equity (Tables) Tables http://rennova.com/role/StockholdersEquity 22 false false R23.htm 00000023 - Disclosure - 8. Income Taxes (Tables) Sheet http://rennova.com/role/IncomeTaxesTables 8. Income Taxes (Tables) Tables http://rennova.com/role/IncomeTaxes 23 false false R24.htm 00000024 - Disclosure - 11. Segment Reporting (Tables) Sheet http://rennova.com/role/SegmentReportingTables 11. Segment Reporting (Tables) Tables http://rennova.com/role/SegmentReporting 24 false false R25.htm 00000025 - Disclosure - 1. Organization and Presentation (Details Narrative) Sheet http://rennova.com/role/OrganizationAndPresentationDetailsNarrative 1. Organization and Presentation (Details Narrative) Details http://rennova.com/role/OrganizationAndPresentation 25 false false R26.htm 00000026 - Disclosure - 2. Accounts Receivable (Details - Accounts receivable) Sheet http://rennova.com/role/AccountsReceivableDetails-AccountsReceivable 2. Accounts Receivable (Details - Accounts receivable) Details http://rennova.com/role/AccountsReceivableTables 26 false false R27.htm 00000027 - Disclosure - 3. Long-Lived Assets (Details - Equipment) Sheet http://rennova.com/role/Long-livedAssetsDetails-Equipment 3. Long-Lived Assets (Details - Equipment) Details http://rennova.com/role/Long-livedAssetsTables 27 false false R28.htm 00000028 - Disclosure - 3. Long-Lived Assets (Details Narrative) Sheet http://rennova.com/role/Long-livedAssetsDetailsNarrative 3. Long-Lived Assets (Details Narrative) Details http://rennova.com/role/Long-livedAssetsTables 28 false false R29.htm 00000029 - Disclosure - 4. Notes Payable (Details-Notes Payable) Notes http://rennova.com/role/NotesPayableDetails-notesPayable 4. Notes Payable (Details-Notes Payable) Details http://rennova.com/role/NotesPayableTables 29 false false R30.htm 00000030 - Disclosure - 4. Notes Payable (Details-Notes Payable Related Party) Notes http://rennova.com/role/NotesPayableDetails-notesPayableRelatedParty 4. Notes Payable (Details-Notes Payable Related Party) Details http://rennova.com/role/NotesPayableTables 30 false false R31.htm 00000031 - Disclosure - 4. Notes Payable (Details Narrative) Notes http://rennova.com/role/NotesPayableDetailsNarrative 4. Notes Payable (Details Narrative) Details http://rennova.com/role/NotesPayableTables 31 false false R32.htm 00000032 - Disclosure - 5. Related Party Transactions (Details Narrative) Sheet http://rennova.com/role/RelatedPartyTransactionsDetailsNarrative 5. Related Party Transactions (Details Narrative) Details http://rennova.com/role/RelatedPartyTransactions 32 false false R33.htm 00000033 - Disclosure - 6. Capital Lease Obligations (Details-Capital leased assets) Sheet http://rennova.com/role/CapitalLeaseObligationsDetails-capitalLeasedAssets 6. Capital Lease Obligations (Details-Capital leased assets) Details http://rennova.com/role/CapitalLeaseObligationsTables 33 false false R34.htm 00000034 - Disclosure - 6. Capital Lease Obligations (Details-Future payments) Sheet http://rennova.com/role/CapitalLeaseObligationsDetails-futurePayments 6. Capital Lease Obligations (Details-Future payments) Details http://rennova.com/role/CapitalLeaseObligationsTables 34 false false R35.htm 00000035 - Disclosure - 6. Capital Lease Obligations (Details Narrative) Sheet http://rennova.com/role/CapitalLeaseObligationsDetailsNarrative 6. Capital Lease Obligations (Details Narrative) Details http://rennova.com/role/CapitalLeaseObligationsTables 35 false false R36.htm 00000036 - Disclosure - 7. Stockholders Equity Earnings (Details-EPS) Sheet http://rennova.com/role/StockholdersEquityEarningsDetails-eps 7. Stockholders Equity Earnings (Details-EPS) Details 36 false false R37.htm 00000037 - Disclosure - 7. Stockholders' Equity (Details - Antidilutive shares) Sheet http://rennova.com/role/StockholdersEquityDetails-AntidilutiveShares 7. Stockholders' Equity (Details - Antidilutive shares) Details http://rennova.com/role/StockholdersEquityTables 37 false false R38.htm 00000038 - Disclosure - 7. Stockholders' Equity (Details Narrative) Sheet http://rennova.com/role/StockholdersEquityDetailsNarrative 7. Stockholders' Equity (Details Narrative) Details http://rennova.com/role/StockholdersEquityTables 38 false false R39.htm 00000039 - Disclosure - 8. Income Taxes (Details-Effective income tax rate) Sheet http://rennova.com/role/IncomeTaxesDetails-effectiveIncomeTaxRate 8. Income Taxes (Details-Effective income tax rate) Details http://rennova.com/role/IncomeTaxesTables 39 false false R40.htm 00000040 - Disclosure - 8. Income Taxes (Details Narrative) Sheet http://rennova.com/role/IncomeTaxesDetailsNarrative 8. Income Taxes (Details Narrative) Details http://rennova.com/role/IncomeTaxesTables 40 false false R41.htm 00000041 - Disclosure - 11. Segment Reporting (Details-Operations) Sheet http://rennova.com/role/SegmentReportingDetails-operations 11. Segment Reporting (Details-Operations) Details http://rennova.com/role/SegmentReportingTables 41 false false R42.htm 00000042 - Disclosure - 11. Segment Reporting (Details-Assets) Sheet http://rennova.com/role/SegmentReportingDetails-assets 11. Segment Reporting (Details-Assets) Details http://rennova.com/role/SegmentReportingTables 42 false false All Reports Book All Reports rnva-20160331.xml rnva-20160331.xsd rnva-20160331_cal.xml rnva-20160331_def.xml rnva-20160331_lab.xml rnva-20160331_pre.xml true true ZIP 61 0001019687-16-006369-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001019687-16-006369-xbrl.zip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end